---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence. Covers upLIFT, Expanded access program in Tumor hyperinsulinism, sunRIZE, RIZE, and XOMA 358 First-in-Human study. 288 evidence topics quoted from 46 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 upLIFT

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Objectives stated in the ClinicalTrials.gov brief summary

> “The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI).”

Source: [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

<a id="topic-3.1.1.1-2"></a>

###### Main objective in the EU Clinical Trials Information System record

> “To evaluate the glycemic efficacy of ersodetug as measured by the number of participants able to achieve a clinically meaningful reduction in continuous glucose requirements compared to baseline.”

Source: [EU Clinical Trials Information System 2024-515447-36-00](https://euclinicaltrials.eu/ctis-public/view/2024-515447-36-00)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Study dates and status in the ClinicalTrials.gov record

> “Study Start (Actual) 2025-04-16”
> “Primary Completion (Estimated) 2027-09”
> “Study Completion (Estimated) 2027-09”
> “First Posted 2025-03-18”
> “Last Update Posted 2026-09-28”
> “Recruiting”
> “No Results Posted”

Source: [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

<a id="topic-3.1.1.2-2"></a>

###### Planned number of sites and countries in the ClinicalTrials.gov record

> “This study is being conducted at approximately 10-15 study sites in approximately 5 countries.”
> “This study has 13 locations”

Source: [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

<a id="topic-3.1.1.2-3"></a>

###### Study locations by country in the ClinicalTrials.gov record

| Country | Locations listed in the record |
| --- | --- |
| United States | “Chicago, Illinois, United States, 60637”; “Bethesda, Maryland, United States, 20892”; “Boston, Massachusetts, United States, 02114”; “Rochester, Minnesota, United States, 55905”; “New York, New York, United States, 10021”; “Canton, Ohio, United States, 44718”; “Portland, Oregon, United States, 97239”; “Houston, Texas, United States, 77030” |
| France | “Clichy, Île-de-France Region, France, 92110” |
| Netherlands | “Rotterdam, South Holland, Netherlands, 3015” |
| Switzerland | “Basel, Canton Basel-Stadt, Switzerland, CH-4001” |
| United Kingdom | “Saint Johns Wood, London, United Kingdom, NW3 2QG”; “Withington, Manchester, United Kingdom, M20 4BX” |

Source: [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

<a id="topic-3.1.1.2-4"></a>

###### European member states, trial dates, and recruitment status in the EU Clinical Trials Information System record

> “Locations France, Netherlands”
> “Start of trial 10/03/2026”
> “Ongoing, recruitment ended”
> “Estimated recruitment start date in EU/EEA: 08/09/2025”
> “Estimated end of trial date in EU/EEA: 09/09/2030”
> “Estimated global end date of the trial: 10/09/2030”

Source: [EU Clinical Trials Information System 2024-515447-36-00](https://euclinicaltrials.eu/ctis-public/view/2024-515447-36-00)

<a id="topic-3.1.1.2-5"></a>

###### Planned conduct primarily in the United States at IND clearance

> “The Company is initiating start-up activities for the study which will be primarily conducted in the U.S. and patient enrollment is planned to commence in the first half of 2025.”

Source: [Rezolute tumor HI IND clearance release (2024)](https://ir.rezolutebio.com/news/detail/337/rezolute-announces-fda-clearance-of-ind-application-for-phase-3-registrational-study-of-rz358-for-treatment-of-hypoglycemia-due-to-tumor-hyperinsulinism)

<a id="topic-3.1.1.2-6"></a>

###### Enrollment in the United States and Europe at fiscal year end 2026

> “The upLIFT study in tumor HI is currently enrolling in the U.S. and Europe.”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

<a id="topic-3.1.1.2-7"></a>

###### Completion of enrollment and expected topline timing

> “today announced that the open-label Phase 3 study of ersodetug in tumor HI (upLIFT) is now fully enrolled and topline data are expected mid-December 2026.”

Source: [Rezolute upLIFT enrollment completion release (2026)](https://ir.rezolutebio.com/news/detail/386/rezolute-announces-completion-of-enrollment-in-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.2-8"></a>

###### Study initiation and current status in the quarterly report

> “The study is now fully enrolled and topline data is expected in mid-December 2026.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

<a id="topic-3.1.1.2-9"></a>

###### Timing of results for the completed study

> “Results for the completed study, including statistical analysis of the primary endpoint, are expected by mid-December 2026.”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Official title in the ClinicalTrials.gov record

> “A Phase 3, Single-Arm, Open-label, Pivotal Study to Evaluate the Efficacy and Safety of Ersodetug Compared to Baseline in Patients With Inadequately Controlled Hypoglycemia Due to Tumor Hyperinsulinism (Tumor HI)”

Source: [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

<a id="topic-3.1.1.3-2"></a>

###### Allocation, intervention model, and masking in the ClinicalTrials.gov record

> “Interventional Model : Single Group Assignment”
> “Masking : None (Open Label)”

Source: [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

<a id="topic-3.1.1.3-3"></a>

###### Study periods in the ClinicalTrials.gov record

> “The study is divided into 3 periods: Screening (up to 4 weeks), Treatment (8 weeks) and either End of Study Follow-up (approximately up to 20 weeks after the last dose) or optional Open Label Extension (OLE) phase (up to 3 years).”

Source: [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

<a id="topic-3.1.1.3-4"></a>

###### Current single-arm, open-label design described by the company

> “The upLIFT Phase 3 registrational study is a single-arm, open-label, pivotal trial in approximately 16 participants with insulinoma or non-islet cell tumors who have uncontrolled hypoglycemia caused by tumor hyperinsulinism (HI).”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.3-5"></a>

###### Multicenter design in the corporate presentation

> “Global, multi - center, single - arm, open - label registrational study”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-3.1.1.3-6"></a>

###### Original randomized, placebo-controlled design at IND clearance

> “The Phase 3 registrational study is a double-blind, randomized, placebo-controlled trial of 24 participants who have inadequately controlled hypoglycemia because of tumor HI.”
> “Up to 24 additional participants may be enrolled into an open-label arm, in participants whose hypoglycemia is being managed by IV glucose in a hospital setting.”
> “The primary endpoint is the change in Level 2 (moderate) and Level 3 (severe) hypoglycemia events by self-monitored blood glucose.”

Source: [Rezolute tumor HI IND clearance release (2024)](https://ir.rezolutebio.com/news/detail/337/rezolute-announces-fda-clearance-of-ind-application-for-phase-3-registrational-study-of-rz358-for-treatment-of-hypoglycemia-due-to-tumor-hyperinsulinism)

<a id="topic-3.1.1.3-7"></a>

###### Design change agreed with the FDA in August 2025

> “At a meeting held with FDA on August 19, 2025, the agency agreed to modifications to the design of the study including removing the need to conduct a double-blind randomized placebo-controlled trial.”
> “The truncated study will include as few as 16 participants and will be limited to the single-arm open-label portion of the upLIFT study, which has been the focus of the Company’s patient recruitment efforts.”

Source: [Rezolute upLIFT design alignment release (2025)](https://ir.rezolutebio.com/news/detail/361/rezolute-announces-alignment-with-fda-on-streamlined-design-for-ongoing-phase-3-trial-of-ersodetug-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.3-8"></a>

###### Removal of the hypoglycemia event endpoint in the annual report

> “At a meeting held with FDA on August 19, 2025, the Agency agreed to modifications to the design of the upLIFT study including removing the need to conduct a randomized, double-blind, placebo-controlled trial with hypoglycemia events as the endpoint.”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Inclusion criteria in the ClinicalTrials.gov record

> “The eligibility criteria of all participants must be evaluated by a multidisciplinary team led by the PI, which must include an oncologist”
> “Male or female participants of ≥18 years of age who provide written informed consent.”
> “Clinical diagnosis of neuroendocrine tumor (NET) (ICT or NICT) with biochemical evidence of tumor hyperinsulinism (hypoglycemia with inappropriately elevated insulin or insulin-like growth factor (IGF)/variant suppression) confirmed via laboratory assessment who have failed to achieve adequate control of hypoglycemia with usual SOC anti-hypoglycemic therapies, per investigator judgement.”
> “Currently requiring IV glucose infusion and/or parenteral nutrition for ≥7 days for the management of refractory hypoglycemia (prior to administration of the 1st dose of ersodetug).”

Source: [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

<a id="topic-3.1.1.4-2"></a>

###### Exclusion criteria in the ClinicalTrials.gov record

> “Evidence of active infection including human immunodeficiency virus, hepatitis B, or hepatitis C (excluding immunization patterns).”
> “Treatment with an investigational drug or device within 30 days or 5 half-lives of the investigational drug (whichever is longer), however, if the treating physician and Medical Monitor consider no significant risk of drug-drug interaction and potential benefit outweighs the risk then the participant may be allowed to participate.”
> “Any out-of-range laboratory value at screening (other than glucose) that is assessed as clinically significant by the investigator.”
> “Known allergy or sensitivity to ersodetug or any component of the drug.”
> “Estimated life expectancy (additional lifespan) due to underlying disease (tumor) is <8 weeks.”

Source: [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

<a id="topic-3.1.1.4-3"></a>

###### Age and sex eligibility in the ClinicalTrials.gov record

> “Ages Eligible for Study 18 Years and older (Adult, Older Adult )”
> “Accepts Healthy Volunteers No”

Source: [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

<a id="topic-3.1.1.4-4"></a>

###### Requirement for continuous parenteral dextrose described by the company

> “The streamlined upLIFT study is a Phase 3, registrational, single-arm, open-label, pivotal trial in approximately 16 participants with insulinoma or paraneoplastic non-islet cell tumors, who require continuous parenteral dextrose because of refractory hypoglycemia.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

Additional sources: [EU Clinical Trials Information System 2024-515447-36-00](https://euclinicaltrials.eu/ctis-public/view/2024-515447-36-00)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Arm and intervention in the ClinicalTrials.gov record

> “Ersodetug (9 mg/kg) + SOC”
> “Every study participant will receive ersodetug doses weekly for 8 weeks alongside their usual treatments for hypoglycemia at a dose of 9 mg/kg.”

Source: [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

<a id="topic-3.1.1.5-2"></a>

###### Pivotal dosing and extension dosing frequency

> “Eligible participants requiring continuous parenteral dextrose will receive ersodetug 9 mg/kg per week for 8 weeks, as an add-on to standard of care.”
> “Following this 8-week pivotal treatment period, all participants may receive ersodetug in long-term extension, with the discretion to decrease the dosing frequency to every 2 to 4 weeks.”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

<a id="topic-3.1.1.5-3"></a>

###### Dosing described in the results release

> “Eligible participants requiring continuous intravenous (IV) glucose receive ersodetug 9 mg/kg per week for 8 weeks, as an add-on to standard of care.”
> “Following this 8-week pivotal treatment period, all participants may receive ersodetug at a reduced dosing frequency in long-term extension.”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.5-4"></a>

###### Once-weekly administration in the corporate presentation

> “Once weekly administration of 9 mg/kg per week as add on to SOC over 8 - week pivotal treatment period”
> “All participants may receive ersodetug in long - term extension”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using Glucose Infusion Rate Reduction of at Least 50% as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Primary and secondary outcome measures in the ClinicalTrials.gov record

| Role | Outcome measure | Time frame |
| --- | --- | --- |
| Primary | “Proportion of participants with clinically meaningful reduction in IV glucose infusion rate from baseline.” | “8 weeks” |
| Secondary | “Change from baseline in average daily IV glucose/dextrose infusion rate (GIR).” | “8 weeks” |
| Secondary | “Change from baseline in average daily total IV glucose delivery (g)” | “8 weeks” |
| Secondary | “Time to complete weaning off IV glucose administration after initiating ersodetug.” | “8 weeks” |

Source: [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

<a id="topic-3.1.1.6.1-2"></a>

###### Primary endpoint and additional endpoints defined by the company

> “The primary endpoint is the proportion of participants able to achieve at least a 50 percent reduction from baseline in GIR, a measure of intravenous glucose dependency for underlying hypoglycemia.”
> “Additional endpoints include the number of participants achieving complete discontinuation of GIR and time to discontinuation, time to discharge from the hospital as applicable, extent of hypoglycemia events and hypoglycemia time in the outpatient setting by self-monitored blood glucose and continuous glucose monitor, respectively, and patient reported quality of life.”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.6.1-3"></a>

###### Responder window within the pivotal treatment phase

> “The study’s primary endpoint is the percent of participants who require intravenous glucose for refractory hypoglycemia that achieve at least a 50 percent reduction from baseline in glucose infusion rate (GIR) within the 8-week pivotal treatment phase.”

Source: [Rezolute upLIFT enrollment completion release (2026)](https://ir.rezolutebio.com/news/detail/386/rezolute-announces-completion-of-enrollment-in-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.6.1-4"></a>

###### Functional status among additional endpoints in the corporate presentation

> “Additional endpoints for GIR, time to discharge from the hospital, and extent of hypoglycemia in the outpatient setting, ECOG status, and patient reported quality of life”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-3.1.1.6.1-5"></a>

###### Glucose infusion rate as an objective endpoint measured in hospital

> “Notably, the GIR assessment in the EAP is the primary endpoint in upLIFT, which measures the number of participants (out of ~16) who achieve at least a 50% reduction in GIR, an objective endpoint in a highly controlled hospital setting.”
> “For statistical significance, 9 of 16 open-label participants need to achieve this threshold.”

Source: [Rezolute sunRIZE and EAP insights release (2026)](https://ir.rezolutebio.com/news/detail/369/rezolute-provides-insights-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-and-shares-findings-from-its-expanded-access-program-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.6.1-6"></a>

###### Expanded access data that informed the endpoint and the design revision

> “This same data cohort was provided to FDA last year in support of the Company’s request for Breakthrough Therapy Designation and subsequently informed the discussion with FDA that led to revision of the Phase 3 upLIFT study in tumor HI to a single arm, open-label study.”
> “In summary, 75% of the patients receiving IV dextrose/total parenteral nutrition (TPN) in the EAP achieved a complete discontinuation of IV dextrose/TPN.”

Source: [Rezolute sunRIZE and EAP insights release (2026)](https://ir.rezolutebio.com/news/detail/369/rezolute-provides-insights-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-and-shares-findings-from-its-expanded-access-program-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.6.1-7"></a>

###### Basis for the streamlined design stated by the company

> “The FDA’s staff and leadership have been very vocal about the desire to responsibly simplify clinical development for rare diseases, particularly when there is real-world evidence of benefit combined with mechanistic plausibility.”
> “We believe that the alignment we have achieved with the agency exemplifies this innovative approach and is substantially based upon the favorable outcomes that we have observed over the last two years treating more than 10 patients with tumor HI under our Expanded Access Program.”

Source: [Rezolute upLIFT design alignment release (2025)](https://ir.rezolutebio.com/news/detail/361/rezolute-announces-alignment-with-fda-on-streamlined-design-for-ongoing-phase-3-trial-of-ersodetug-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.6.1-8"></a>

###### Design modification to improve the likelihood of demonstrating efficacy

> “In an effort to align with FDA guidance and improve the likelihood of demonstrating efficacy, the FDA allowed us to modify the upLIFT trial design.”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

<a id="topic-3.1.1.6.1-9"></a>

###### Glucose infusion rate assessment contrasted with self-monitored measures in sunRIZE

> “These results reveal the clinically impactful hypoglycemia-correcting activity of ersodetug in an unbiased GIR assessment in patients with HI caused by varying tumor types.”
> “This further highlights the aberrant outcome from the recently completed randomized, placebo-controlled, Phase 3 sunRIZE study in pediatric congenital HI, where we believe that self-monitored glycemic measures were confounded by divergent caretaker behaviors stemming from functional unblinding to treatment status by real-time glucose monitoring.”

Source: [Rezolute upLIFT interim release (2026)](https://ir.rezolutebio.com/news/detail/378/rezolute-announces-positive-interim-data-for-its-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.6.1-10"></a>

###### Clinical relevance of parenteral glucose dependence in tumor hyperinsulinism (insulinoma)

> “Supportive strategies such as frequent carbohydrate intake or continuous parenteral dextrose infusion are often required but are burdensome and do not provide durable control, and parenteral infusions may prevent hospital discharge.”
> “Assessments of efficacy focused on changes in GIR (since most participants initially required parenteral dextrose to correct refractory hypoglycemia) and also included assessments of hypoglycemia by CGM (described below), number of hospitalization days in the month before and after ersodetug initiation, and overall survival.”
> “Most individuals were receiving parenteral dextrose during baseline, which by intent likely ameliorated hypoglycemia, thus masking the severity of baseline glycemic measures by CGM.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.1.6.1-11"></a>

###### Success threshold of a lower 95% confidence bound above 30%

> “where statistical significance would be achieved if the lower bound of the 95% confidence interval of the point estimate exceeds 30% (equating to a responder rate of ~9 of 16 participants)”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

<a id="topic-3.1.1.6.1-12"></a>

###### Agreement with the FDA on an adequate and well-controlled program

> “Alignment with FDA on tumor HI clinical data package which support BLA filing, including a streamlined yet adequate and well - controlled Phase 3 clinical program”

Source: [Rezolute investor event presentation (2025)](https://www.sec.gov/Archives/edgar/data/1509261/000110465925109559/tm2530840d1_ex99-1.htm)

Additional sources: [EU Clinical Trials Information System 2024-515447-36-00](https://euclinicaltrials.eu/ctis-public/view/2024-515447-36-00)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Planned enrollment in the ClinicalTrials.gov record

> “Enrollment (Estimated) 16”
> “The study will enroll approximately 16 participants, all with a diagnosis of tumor HI (insulin- or IGF producing tumors).”

Source: [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

<a id="topic-3.1.1.7.1-2"></a>

###### Enrollment of 16 participants at study completion of enrollment

> “The upLIFT study is a single-arm, open-label, registrational study in 16 participants with insulinoma or non-islet cell tumors who have uncontrolled hypoglycemia caused by tumor HI.”

Source: [Rezolute upLIFT enrollment completion release (2026)](https://ir.rezolutebio.com/news/detail/386/rezolute-announces-completion-of-enrollment-in-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.7.1-3"></a>

###### Participants included in the preliminary primary endpoint evaluation

> “To date, 13 participants have met the responder criterion, including 12 who also achieved a complete discontinuation of IV glucose.”
> “Three participants are still in the pivotal period of the study, including two who have not yet met the responder criterion.”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.7.1-4"></a>

###### Criterion for statistical significance of the responder proportion

> “To achieve statistical significance for the endpoint, the lower bound of the 95% confidence interval for percent of patients responding must exceed 30%, which equates to at least 9 responders (≥56%), based on enrollment of 16 participants.”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.7.1-5"></a>

###### Responder rate and confidence interval required for 16 participants

> “For statistical significance, the lower bound of the 95% confidence interval (CI) for the percent responder rate must be ≥30%, equating to a response rate of at least 56% (95% CI of 30-80%) for 16 participants.”

Source: [Rezolute upLIFT enrollment completion release (2026)](https://ir.rezolutebio.com/news/detail/386/rezolute-announces-completion-of-enrollment-in-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Classification of the participant who entered hospice as a non-responder

> “The reduction and eventual discontinuation of intravenous glucose were undertaken in the setting of hospice transition, so the participant is being counted as a non-responder for purposes of assessing the primary endpoint.”

Source: [Rezolute upLIFT interim release (2026)](https://ir.rezolutebio.com/news/detail/378/rezolute-announces-positive-interim-data-for-its-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.7.2-2"></a>

###### Denominator of 16 enrolled participants for the significance threshold

> “To achieve statistical significance for the endpoint, the lower bound of the 95% confidence interval for the percent of patients responding must exceed 30%, which equates to at least 9 responders (≥56%), based on enrollment of 16 participants.”

Source: [Rezolute prospectus supplement (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926126478/tm2627558-6_424b5.htm)

<a id="topic-3.1.1.7.2-3"></a>

###### Final statistical analysis pending after the preliminary evaluation

> “The results announced to date are preliminary, are based on data evaluation that”
> “precedes completion of the study, and remain subject to change based on the completed study data and final statistical analysis.”

Source: [Rezolute prospectus supplement (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926126478/tm2627558-6_424b5.htm)

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### Preliminary disposition at the November 2026 data evaluation

> “Three participants are still in the pivotal period of the study, including two who have not yet met the responder criterion.”
> “As previously reported, one participant discontinued the study early and chose to enter home hospice care, and died one week later due to cancer progression.”
> “This participant has been classified as a non-responder for purposes of the primary endpoint.”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.8.1-2"></a>

###### Withdrawal of the participant with stage 4 colon cancer at the interim update

> “One of the 8 enrolled participants withdrew study consent and discontinued ersodetug and all other non-palliative therapies prior to completion of the pivotal treatment phase.”
> “This patient had Stage 4 metastatic colon cancer and a poor Eastern Cooperative Oncology Group performance status (ECOG 4).”
> “The participant elected to be discharged from the hospital to receive hospice care at home, where they died one week later due to cancer progression.”

Source: [Rezolute upLIFT interim release (2026)](https://ir.rezolutebio.com/news/detail/378/rezolute-announces-positive-interim-data-for-its-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.8.1-3"></a>

###### Continuation into the open-label extension at the interim update

> “All participants that have completed the 8-week pivotal treatment period have elected to continue into the open-label extension, with a cumulative treatment duration of up to 6 months.”

Source: [Rezolute upLIFT interim release (2026)](https://ir.rezolutebio.com/news/detail/378/rezolute-announces-positive-interim-data-for-its-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### Tumor types of the 16 enrolled participants (insulinoma and non-islet cell tumor)

> “The 16 enrolled participants include four with non-islet cell tumors and 12 with insulin-secreting malignant islet cell tumors (insulinomas).”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.8.2-2"></a>

###### Mechanism of hypoglycemia in the enrolled participants

> “Of the 16 enrolled participants, four were experiencing hypoglycemia due to paraneoplastic secretion of IGF-2 variants from non-islet cell tumors, and the remainder were due to insulin-secreting malignant islet cell tumors (insulinomas).”

Source: [Rezolute prospectus supplement (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926126478/tm2627558-6_424b5.htm)

<a id="topic-3.1.1.8.2-3"></a>

###### Tumor types of the first 8 participants at the interim update

> “With 8 participants enrolled in upLIFT to date, comprising both insulinoma and non-islet cell tumor hypoglycemia, the Company is midway through enrollment of the planned study sample size of 16 participants.”

Source: [Rezolute upLIFT interim release (2026)](https://ir.rezolutebio.com/news/detail/378/rezolute-announces-positive-interim-data-for-its-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### Preliminary primary endpoint result at the November 2026 data evaluation

> “today announced positive results from the ongoing open-label Phase 3 upLIFT study of ersodetug in tumor HI, in which the primary efficacy endpoint has been achieved”
> “To date, 13 participants have met the responder criterion, including 12 who also achieved a complete discontinuation of IV glucose.”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.8.3-2"></a>

###### Preliminary results subject to change before the final analysis

> “Although the primary efficacy endpoint has been achieved based on preliminary results, these results may change upon completion of the study”
> “Three participants remain in the pivotal period of the study, including two who have not yet met the responder criterion, and the final proportion of responders, and the lower bound of the 95% confidence interval for that proportion, may differ from the results announced to date.”

Source: [Rezolute prospectus supplement (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926126478/tm2627558-6_424b5.htm)

<a id="topic-3.1.1.8.3-3"></a>

###### Preliminary interim result in the first 8 participants (June 2026)

> “Of the 8 participants enrolled, 6 have already met the responder criterion for the study’s primary endpoint, which is the number of participants achieving at least a 50 percent reduction from baseline in intravenous glucose requirements (glucose infusion rate; GIR) within the 8-week pivotal treatment phase.”
> “Each of these 6 participants also achieved a complete discontinuation of intravenous glucose requirements with the administration of ersodetug.”

Source: [Rezolute upLIFT interim release (2026)](https://ir.rezolutebio.com/news/detail/378/rezolute-announces-positive-interim-data-for-its-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.8.3-4"></a>

###### Preliminary update of the first 8 participants to 7 responders

> “Earlier this year, the Company announced that 7 of the 8 participants enrolled in the first half of the study met the responder criterion for the study’s primary endpoint.”
> “Furthermore, each of these participants also achieved complete discontinuation of intravenous glucose with the administration of ersodetug.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### Preliminary safety in the pivotal and extension phases (November 2026)

> “Ersodetug has been well-tolerated to date in the pivotal and extension phases of the study, with no drug-related safety findings attributed to ersodetug.”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.8.5-2"></a>

###### Preliminary drug-related adverse events stated in the prospectus supplement

> “Ersodetug has been well-tolerated to date in the pivotal and extension phases of the study, with no drug-related adverse events or other safety findings attributed to ersodetug.”

Source: [Rezolute prospectus supplement (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926126478/tm2627558-6_424b5.htm)

<a id="topic-3.1.1.8.5-3"></a>

###### Preliminary safety at the interim update (June 2026)

> “Ersodetug has been well-tolerated in the pivotal and extension phases of the study, with no drug-related adverse events or other safety findings reported to date.”

Source: [Rezolute upLIFT interim release (2026)](https://ir.rezolutebio.com/news/detail/378/rezolute-announces-positive-interim-data-for-its-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.8.5-4"></a>

###### Death due to cancer progression after withdrawal to hospice

> “The participant elected to be discharged from the hospital to receive hospice care at home, where they died one week later due to cancer progression.”

Source: [Rezolute upLIFT interim release (2026)](https://ir.rezolutebio.com/news/detail/378/rezolute-announces-positive-interim-data-for-its-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary

- Design: upLIFT is a single-arm, open-label trial of 16 participants with no concurrent comparator, so the responder proportion is judged against a prespecified threshold (lower bound of the 95% confidence interval above 30%). The source documents word the threshold as “must exceed 30%” and as “must be ≥30%”.
- Status of the data: the results are preliminary and come from company press releases and SEC filings; no publication, congress presentation, or registry results exist. At the 13 November 2026 evaluation, 3 participants remained in the pivotal period, and the final responder proportion and its confidence interval may differ.
- Applicability: participants are adults who require IV glucose or parenteral nutrition despite standard-of-care therapies, with the primary endpoint measured in a hospital setting, and receive ersodetug as an add-on; the results describe the most severe presentation. Results by tumor type (insulinoma or non-islet cell tumor) and patient-reported quality of life have not been reported.
- One participant with stage 4 metastatic colon cancer withdrew to hospice and was counted as a non-responder; outcomes in participants with poor performance status are therefore represented by a single case.
- Registry records lag the company: ClinicalTrials.gov still lists the trial as recruiting, while the company reports enrollment complete.

Source: [Rezolute upLIFT enrollment completion release (2026)](https://ir.rezolutebio.com/news/detail/386/rezolute-announces-completion-of-enrollment-in-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism); [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism); [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm); [Rezolute prospectus supplement (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926126478/tm2627558-6_424b5.htm); [Rezolute upLIFT interim release (2026)](https://ir.rezolutebio.com/news/detail/378/rezolute-announces-positive-interim-data-for-its-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism); [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

<a id="heading-3.1.2"></a>

#### 3.1.2 Expanded Access Program in Tumor Hyperinsulinism

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Objective of the peer-reviewed case series: insulinoma and cervical neuroendocrine carcinoma

> “We retrospectively report outcomes from compassionate use of ersodetug in 8 individuals with refractory hypoglycemia due to tumor HI.”
> “this case series retrospectively reports on the experience of 8 individuals with refractory hypoglycemia due to tumor HI (metastatic insulin-producing tumors) who were treated with ersodetug on a compassionate use basis via an expanded access program (EAP).”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.1-2"></a>

###### Purpose of the expanded access program

> “The EAP was initiated to provide compassionate access to ersodetug for individuals with severe, refractory hypoglycemia due to HI.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

> “for a variety of HI indications for the purpose of making ersodetug available on a compassionate use basis when patients have refractory hypoglycemia and cannot access a clinical trial.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

<a id="topic-3.1.2.1-3"></a>

###### Objective of the ENDO 2026 case series poster

> “We examined the real-world outcomes from a case-series of patients with refractory hypoglycemia due to metastatic insulin-producing neuroendocrine tumors who received ersodetug for compassionate use as part of an EAP”

Source: [Patti et al. (2026)](https://rezolutebio.com/wp-content/uploads/2026/06/PSTR006_RZLT_ENDO-poster_Tumor-H_3x4_ssREL.pdf)

<a id="topic-3.1.2.1-4"></a>

###### Objective of the NANETS 2024 poster

> “To report the case experiences from a cohort of patients who have received RZ358 to treat tumorHI.”

Source: [Strosberg et al. (2024)](https://rezolutebio.com/wp-content/uploads/2025/10/NANETS-2024-Poster_Final.pdf)

<a id="topic-3.1.2.1-5"></a>

###### Objective of the single published case: metastatic insulinoma

> “We report the successful use of RZ358, a novel human anti–insulin receptor monoclonal antibody, in a patient with metastatic insulinoma in whom severe, refractory hypoglycemia developed after peptide receptor radionuclide therapy with lutetium Lu 177 dotatate.”

Source: [Osataphan et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10506502/)

<a id="topic-3.1.2.1-6"></a>

###### Purpose of the intermediate-size cohort expanded access program: insulinoma and NICTH

> “This expanded access program is intended to provide ersodetug, an investigational drug, to eligible participants who suffer from inadequately controlled hypoglycemia due to tumor-associated hyperinsulinism and are unable to participate in ersodetug clinical trial.”

Source: [ClinicalTrials.gov NCT07262970](https://clinicaltrials.gov/study/NCT07262970)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Enrollment period, data cutoff, and countries in the peer-reviewed case series

> “Eight individuals with refractory hypoglycemia secondary to HI whose glycemic needs were not adequately managed by standard-of-care therapies were enrolled in the EAP beginning in November 2022; data were collected until the data cutoff of August 2025.”
> “were enrolled in the EAP in the United States (n = 7) and the Netherlands (n = 1)”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.2-2"></a>

###### First patient treated at a single U.S. center under FDA emergency use authorization

> “We obtained emergency use authorization from the Food and Drug Administration, approval from the institutional review board of Beth Israel Deaconess Medical Center, and written informed consent from the patient.”

Source: [Osataphan et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10506502/)

<a id="topic-3.1.2.2-3"></a>

###### Investigators in the United States and Europe, as stated by the company in January 2026

> “Over the past two years, Rezolute has collaborated with investigators across the United States and in Europe to provide ersodetug to more than a dozen patients with severe and refractory hypoglycemia due to tumor HI, including malignant pancreatic neuroendocrine tumors (insulinomas) and non-islet cell tumors.”

Source: [Rezolute sunRIZE and EAP insights release (2026)](https://ir.rezolutebio.com/news/detail/369/rezolute-provides-insights-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-and-shares-findings-from-its-expanded-access-program-in-tumor-hyperinsulinism)

<a id="topic-3.1.2.2-4"></a>

###### Status, dates, and location of the intermediate-size cohort expanded access program

| Field | Quoted record |
| --- | --- |
| Expanded access status | “Available” |
| Other study ID number | “RZ358-303” |
| First submitted | “2025-11-21” |
| First posted | “2025-12-04” |
| Last update posted | “2026-10-07” |
| Location | “New Orleans, Louisiana, United States, 70112” |

Source: [ClinicalTrials.gov NCT07262970](https://clinicaltrials.gov/study/NCT07262970)

<a id="topic-3.1.2.2-5"></a>

###### Program continuing after completion of upLIFT enrollment

> “The Company plans to continue its expanded access program for purposes of providing ersodetug on a compassionate use basis to individuals living with serious and refractory hypoglycemia due to tumor HI.”

Source: [Rezolute upLIFT enrollment completion release (2026)](https://ir.rezolutebio.com/news/detail/386/rezolute-announces-completion-of-enrollment-in-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Retrospective case series of single-patient compassionate use requests

> “Enrollment was initiated by a treating physician through a named patient request (single-patient investigational new drug application) to the country health authority and was approved by local institutional review board, if required.”
> “Written informed consent was obtained from all individuals before treatment initiation.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.3-2"></a>

###### Change from an earlier compassionate use framework to a tumor HI-specific framework

> “The first 2 individuals were enrolled under an earlier compassionate-use program framework; a subsequent, tumor HI–specific framework was implemented during the course of the third patient's treatment and applied to all remaining individuals.”
> “The updated framework incorporated a higher weekly dose that had shown superior effectiveness in early experience”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.3-3"></a>

###### Overlap of the first patient with the published single case

> “For Patient 1, the continuous glucose monitoring (CGM) and glucose infusion rate (GIR) data for the 90-day pre- and post-treatment windows presented herein also were previously reported in a single case report”
> “all other efficacy data for this patient are new.”
> “This patient was the first to receive ersodetug for tumor HI, with detailed results previously reported in a case report”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.3-4"></a>

###### Role of the expanded access data in Breakthrough Therapy Designation and the upLIFT redesign

> “This same data cohort was provided to FDA last year in support of the Company’s request for Breakthrough Therapy Designation and subsequently informed the discussion with FDA that led to revision of the Phase 3 upLIFT study in tumor HI to a single arm, open-label study.”

Source: [Rezolute sunRIZE and EAP insights release (2026)](https://ir.rezolutebio.com/news/detail/369/rezolute-provides-insights-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-and-shares-findings-from-its-expanded-access-program-in-tumor-hyperinsulinism)

> “is substantially based upon the favorable outcomes that we have observed over the last two years treating more than 10 patients with tumor HI under our Expanded Access Program.”

Source: [Rezolute upLIFT design alignment release (2025)](https://ir.rezolutebio.com/news/detail/361/rezolute-announces-alignment-with-fda-on-streamlined-design-for-ongoing-phase-3-trial-of-ersodetug-in-tumor-hyperinsulinism)

<a id="topic-3.1.2.3-5"></a>

###### Design of the intermediate-size cohort expanded access program

| Field | Quoted record |
| --- | --- |
| Official title | “Intermediate-Size Cohort EAP for Ersodetug in Patients With Refractory Hypoglycemia Due to Tumor-Associated Hyperinsulinism (Tumor HI) Who Are Unable to Participate in a Clinical Trial” |
| Study type | “Expanded Access” |
| Expanded access type | “Intermediate-size Population” |
| Condition | “Tumor-associated Hyperinsulinism (Tumor HI)” |
| Sponsor | “Rezolute” |

Source: [ClinicalTrials.gov NCT07262970](https://clinicaltrials.gov/study/NCT07262970)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Eligibility in the peer-reviewed case series

> “Individuals were eligible regardless of tumor type, prior therapies, or comorbidities, provided they were clinically stable for infusion.”
> “All listed diagnoses were confirmed by relevant laboratory, imaging and pathology over the treatment courses and prior to initiating ersodetug.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.4-2"></a>

###### Inclusion criteria of the intermediate-size cohort expanded access program: insulinoma and NICTH

> “Uncontrolled hypoglycemia due to documented tumor HI (including but not limited to: insulin/pro-insulin producing pancreatic/non-pancreatic neuroendocrine tumors, insulin-like growth factor-producing NICTH) that is not adequately managed with available SoC anti-hypoglycemic therapies (per Treating Physician's judgement).”
> “Inability to participate in any ersodetug clinical trial.”
> “Women of childbearing potential (WOCBP) must not be pregnant or breast feeding, and must be willing to use effective contraceptive measures or practice complete sexual abstinence to prevent pregnancy for the duration of the Cohort EAP AND for at least 5 months after receiving the last dose of ersodetug.”

Source: [ClinicalTrials.gov NCT07262970](https://clinicaltrials.gov/study/NCT07262970)

<a id="topic-3.1.2.4-3"></a>

###### Exclusion criteria of the intermediate-size cohort expanded access program

> “Evidence of active infection including (but not limited to) human immunodeficiency virus, hepatitis B, or hepatitis C.”
> “Known allergy or sensitivity to ersodetug or any component of the drug.”
> “Treatment with an investigational drug or device within 30 days or 5 t½ of the investigational drug before the planned 1st dose of ersodetug, whichever is longer.”

Source: [ClinicalTrials.gov NCT07262970](https://clinicaltrials.gov/study/NCT07262970)

<a id="topic-3.1.2.4-4"></a>

###### Age and sex eligibility of the intermediate-size cohort expanded access program

| Field | Quoted record |
| --- | --- |
| Ages eligible | “18 Years and older” |
| Sexes eligible | “All” |

Source: [ClinicalTrials.gov NCT07262970](https://clinicaltrials.gov/study/NCT07262970)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Dose, route, and schedule in the peer-reviewed case series

> “Ersodetug was administered intravenously over 30 minutes at an initial dose of 6 or 9 mg/kg, given either weekly or every other week initially, followed by a frequency of every 2-5 weeks, as appropriate, at the discretion of the treating physician.”
> “Dose adjustments, including titration and changes in dosing frequency, were made based on glycemic response, tolerability, and clinical course.”
> “After exploratory dose-ranging in the first 2 participants, the initiation dose regimen was standardized in subsequent participants to 9 mg/kg weekly, followed by de-escalation as indicated.”
> “One participant required escalation from 9 to 12 mg/kg every other week.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.5-2"></a>

###### Concomitant standard-of-care and tumor-directed therapy

> “Supportive therapies, including use of ongoing standard-of-care antihypoglycemic treatments, were noted and recorded.”
> “Individuals resumed tumor-directed therapies or procedures as deemed appropriate by the multidisciplinary clinical care team, and these interventions were systematically recorded as part of the observational dataset.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.5-3"></a>

###### Drug supplied at no cost by the manufacturer

> “Rezolute, Inc. (Redwood City, CA, USA) provided ersodetug at no cost to participating institutions for use under health authority–authorized compassionate use programs.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.5-4"></a>

###### Dose regimen by patient in the company table of 9 patients

| Patient | Ersodetug dose regimen (dose/frequency) |
| --- | --- |
| Patient 1 | “6-9 mg/kg every 1-4 weeks” |
| Patient 2 | “6-9 mg/kg every 1-2 weeks” |
| Patient 3 | “9 mg/kg, every 1-2 weeks” |
| Patient 4 | “9-12 mg/kg every 1-2 weeks” |
| Patient 5 | “9 mg/kg every 1-3 weeks” |
| Patient 6 | “9 mg/kg every 1-2 weeks” |
| Patient 7 | “6-9 mg/kg every 1-2 weeks” |
| Patient 8 | “9 mg/kg every 1-2 weeks” |
| Patient 9 | “9 mg/kg every 1-3 weeks” |

Source: [Rezolute EAP patient profiles (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926001556/tm262357d1_ex99-2.htm)

<a id="topic-3.1.2.5-5"></a>

###### Dosing in the ENDO 2026 case series poster

> “All patients received ersodetug in open-label fashion at doses of 6 or 9 mg/kg every 1-2 weeks initially, followed by a frequency of every 2-4 weeks as tolerated, as add on to standard of care (e.g. diazoxide, somatostatin analogues, etc.), which could be weaned as appropriate”

Source: [Patti et al. (2026)](https://rezolutebio.com/wp-content/uploads/2026/06/PSTR006_RZLT_ENDO-poster_Tumor-H_3x4_ssREL.pdf)

<a id="topic-3.1.2.5-6"></a>

###### Dosing in the NANETS 2024 poster

> “Ersodetug was initiated at 6 or 9mg/kg every 1-2 weeks (by 30-min intravenous infusion), and titrated to response, at physician discretion.”

Source: [Strosberg et al. (2024)](https://rezolutebio.com/wp-content/uploads/2025/10/NANETS-2024-Poster_Final.pdf)

<a id="topic-3.1.2.5-7"></a>

###### Dosing range stated by the company

> “Generally, dosing for tumor HI patients in the EAP has been either 6 mg/kg or 9 mg/kg every 1-4 weeks.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

<a id="topic-3.1.2.5-8"></a>

###### Intervention in the intermediate-size cohort expanded access program

| Field | Quoted record |
| --- | --- |
| Intervention | “Drug: Ersodetug (9 mg/kg) + SOC” |
| Description | “Open-Label Participants with a diagnosis of Tumor HI (insulin- or IGF-producing tumors)” |

Source: [ClinicalTrials.gov NCT07262970](https://clinicaltrials.gov/study/NCT07262970)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Discontinuation of Parenteral Glucose as the Primary Outcome

<a id="topic-3.1.2.6.1-1"></a>

###### No prespecified primary outcome: efficacy assessments centered on glucose infusion rate

> “Assessments of efficacy focused on changes in GIR (since most participants initially required parenteral dextrose to correct refractory hypoglycemia) and also included assessments of hypoglycemia by CGM (described below), number of hospitalization days in the month before and after ersodetug initiation, and overall survival.”
> “Eastern Cooperative Oncology Group (ECOG) performance status was used to assess functional ability.”
> “The ersodetug dosing regimen, treatment duration, and safety observations (serious adverse events and drug-related serious adverse events) were also recorded and assessed.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.6.1-2"></a>

###### Parenteral dextrose at baseline masks hypoglycemia measured by continuous glucose monitoring

> “Most individuals were receiving parenteral dextrose during baseline, which by intent likely ameliorated hypoglycemia, thus masking the severity of baseline glycemic measures by CGM.”
> “Therefore, changes from baseline in CGM should be interpreted accordingly.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.6.1-3"></a>

###### Continuous glucose monitoring outcomes and windows

> “CGM data were analyzed for mean sensor glucose and percent of time in predefined glycemic ranges (eg, <70 mg/dL, <54 mg/dL, and >180 mg/dL).”
> “Baseline for CGM purposes was defined as the period up to 90 days before the first dose of ersodetug, and the evaluable window was defined as the period up to 90 days after initiation; longer follow-up CGM data were included in a sensitivity analysis.”
> “Its pharmacokinetic characteristics informed selection of a 90-day evaluable window during which drug concentrations were expected to be at steady-state for most individuals.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.6.1-4"></a>

###### Parenteral infusion as a barrier to discharge and to tumor-directed therapy

> “Supportive strategies such as frequent carbohydrate intake or continuous parenteral dextrose infusion are often required but are burdensome and do not provide durable control, and parenteral infusions may prevent hospital discharge.”
> “These functional gains enabled most individuals to pursue tumor-directed therapies, including chemotherapy, surgery, and hepatic arterial embolization, underscoring the importance of glycemic stabilization as a prerequisite for oncologic care in this population.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.6.1-5"></a>

###### Glucose infusion rate as the focus of the ENDO 2026 case series analysis

> “Glycemic and safety outcomes were reported and analyzed descriptively with a focus on the change from baseline in the GIR as a function of hypoglycemia”

Source: [Patti et al. (2026)](https://rezolutebio.com/wp-content/uploads/2026/06/PSTR006_RZLT_ENDO-poster_Tumor-H_3x4_ssREL.pdf)

<a id="topic-3.1.2.6.1-6"></a>

###### Glucose infusion rate assessment shared with the upLIFT primary endpoint

> “Notably, the GIR assessment in the EAP is the primary endpoint in upLIFT, which measures the number of participants (out of ~16) who achieve at least a 50% reduction in GIR, an objective endpoint in a highly controlled hospital setting.”

Source: [Rezolute sunRIZE and EAP insights release (2026)](https://ir.rezolutebio.com/news/detail/369/rezolute-provides-insights-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-and-shares-findings-from-its-expanded-access-program-in-tumor-hyperinsulinism)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Peer-reviewed case series: 8 participants

> “Eight adults (4M/4F; 24-74 years; Eastern Cooperative Oncology Group [ECOG] 1-3) received ersodetug for insulin-secreting tumors (metastatic insulinoma, n = 7; cervical neuroendocrine carcinoma, n = 1).”
> “All 8 individuals had CGM data available.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.7.1-2"></a>

###### ENDO 2026 poster: 9 patients

> “As of the data cut, 9 patients with refractory hypoglycemia due to malignant insulinoma had received ersodetug and are included in this retrospective case series report”

Source: [Patti et al. (2026)](https://rezolutebio.com/wp-content/uploads/2026/06/PSTR006_RZLT_ENDO-poster_Tumor-H_3x4_ssREL.pdf)

<a id="topic-3.1.2.7.1-3"></a>

###### Company table filed with the SEC: 9 patients

> “Presented in a table filed today on Form 8-K with the U.S. Securities and Exchange Commission are cumulative data from the initial 9 participants in the EAP, including patient characteristics, ersodetug dosing, and observed outcomes.”

Source: [Rezolute sunRIZE and EAP insights release (2026)](https://ir.rezolutebio.com/news/detail/369/rezolute-provides-insights-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-and-shares-findings-from-its-expanded-access-program-in-tumor-hyperinsulinism)

<a id="topic-3.1.2.7.1-4"></a>

###### ENDO 2026 company release: 9 patients with malignant insulinoma and non-islet cell tumors

> “A third poster presentation highlighted favorable outcomes from a case series report of 9 patients with refractory hypoglycemia due to malignant insulinoma and non-islet cell tumors (tumor HI), demonstrating that 75% of the patients receiving IV dextrose/total parenteral nutrition (TPN) in the EAP achieved a complete discontinuation of IV dextrose/TPN.”

Source: [Rezolute ENDO presentations release (2026)](https://ir.rezolutebio.com/news/detail/380/rezolute-highlights-results-presented-from-natural-history-outcomes-studies-and-its-ersodetug-clinical-program-in-hyperinsulinism-at-annual-meeting-of-the-endocrine-society)

<a id="topic-3.1.2.7.1-5"></a>

###### NANETS 2024 poster: 5 patients

> “Five adult patients (2M/3F) with refractory hypoglycemia due to metastatic insulin producing tumors received treatment with ersodetug after FDA/IRB-approval.”

Source: [Strosberg et al. (2024)](https://rezolutebio.com/wp-content/uploads/2025/10/NANETS-2024-Poster_Final.pdf)

<a id="topic-3.1.2.7.1-6"></a>

###### Total patients treated under the program, as stated by the company: more than 10 to 13

> “More than 10 tumor HI patients to date have successfully been treated in the Expanded Access Program.”

Source: [Rezolute congenital HI breakthrough therapy release (2025)](https://ir.rezolutebio.com/news/detail/345/rezolute-receives-breakthrough-therapy-designation-from-fda-for-ersodetug-in-the-treatment-of-hypoglycemia-due-to-congenital-hyperinsulinism)

> “13 patients with tumor HI treated in our Expanded Access Program (EAP) to date”

Source: [Rezolute investor event presentation (2025)](https://www.sec.gov/Archives/edgar/data/1509261/000110465925109559/tm2530840d1_ex99-1.htm)

> “To date, we have received numerous inbound physician inquiries regarding the use of ersodetug in patients with tumor HI caused by metastatic insulinomas or non-islet cell tumors, which led to compassionate use treatment in an expanded access program in more than a dozen patients.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Analysis population and evaluation periods in the peer-reviewed case series

> “In this retrospective analysis, observational data were collected until August 2025 (or earlier treatment discontinuation) in all individuals who received at least one infusion of ersodetug and had available follow-up data.”
> “For standardization of glycemic assessments, baseline was defined as the period up to 90 days prior to ersodetug initiation.”
> “The evaluable period was defined as the time from ersodetug initiation until the data cutoff (August 2025) or treatment discontinuation.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.7.2-2"></a>

###### Parenteral glucose subset: 7 of 8 participants

> “Of the 7 individuals who were receiving parenteral glucose, including one on home TPN, baseline GIRs at ersodetug initiation ranged from 3.1 to 7.0 mg/kg/min.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

> “Seven of the 8 patients receiving parenteral glucose at baseline achieved at least a 50% reduction”

Source: [Patti et al. (2026)](https://rezolutebio.com/wp-content/uploads/2026/06/PSTR006_RZLT_ENDO-poster_Tumor-H_3x4_ssREL.pdf)

<a id="topic-3.1.2.7.2-3"></a>

###### Paired nonparametric comparisons without formal hypothesis testing

> “Changes in percent time in glycemic ranges and medication counts were assessed from paired comparisons of the baseline period (up to 90 days) with the post-initiation evaluable period (up to 90 days) using the Wilcoxon-signed rank test in R.”
> “95% intervals could not be constructed due to the sample size [N = 8] and discrete nature of the test”
> “Strength of statistical evidence was evaluated using nominal P-values, but no formal or prespecified hypothesis testing was conducted due to the retrospective nature of the report and limited sample size.”
> “A statistical analysis plan with additional details of the statistical methods was developed after primary data analyses and is available in the Supplemental Appendix”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Treatment duration, dosing de-escalation, and deaths in the peer-reviewed case series

> “Most individuals (n = 6/8) were able to decrease the dosing frequency of ersodetug after hospital discharge.”
> “The median treatment duration with ersodetug of 11.5 months (range 5-17 months; ongoing in 2 individuals) also corresponded to patient lifespan and overall survival in the setting of metastatic disease.”
> “Of the individuals who died (n = 6), tumor progression and sepsis were cited as the cause, unrelated to the investigational drug.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.1-2"></a>

###### Treatment duration and survival by patient in the company table of 9 patients

| Patient | Total duration of ersodetug therapy (months) | Overall survival (months) |
| --- | --- | --- |
| Patient 1 | “13” | “14” |
| Patient 2 | “5” | “5” |
| Patient 3 | “5” | “5” |
| Patient 4 | “14” | “14” |
| Patient 5 | “22 (ongoing)” | “22 (living)” |
| Patient 6 | “18 (ongoing)” | “18 (living)” |
| Patient 7 | “6” | “6” |
| Patient 8 | “1.5” | “1.5” |
| Patient 9 | “10” | “10” |

Source: [Rezolute EAP patient profiles (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926001556/tm262357d1_ex99-2.htm)

<a id="topic-3.1.2.8.1-3"></a>

###### Critically ill patient who died of sepsis before response could be assessed: company table

> “Patient was critically ill when treatment commenced and died of sepsis prior to determination of whether there was a therapeutic effect”

Source: [Rezolute EAP patient profiles (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926001556/tm262357d1_ex99-2.htm)

<a id="topic-3.1.2.8.1-4"></a>

###### First two patients still receiving treatment in October 2023

> “The patient began receiving treatment with RZ358 in September 2023”
> “Notably, the individual with metastatic insulinoma has remained on RZ358 for nearly a year.”

Source: [Rezolute tumor HI evidence release (2023)](https://ir.rezolutebio.com/news/detail/318/rezolute-announces-further-evidence-of-rz358s-efficacy-in-tumor-mediated-hyperinsulinism)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Demographics and clinical characteristics in the peer-reviewed case series

> “All individuals were White; 7 identified as non-Hispanic and one as Hispanic.”
> “Seven individuals had metastatic insulinoma and one had neuroendocrine carcinoma of the cervix.”
> “The cohort was characterized by predominantly metastatic disease with substantial hepatic involvement and variable but often abnormal liver biochemistry, along with renal function ranging from normal to mildly impaired at the time of ersodetug initiation.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.2-2"></a>

###### Hospitalization at entry stated in the text of the peer-reviewed case series

> “Six of the 8 individuals were hospitalized at EAP entry (median, 28 days; range, 4-66 days), largely due to glycemic instability and the need for inpatient or intensive parenteral glucose support.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.2-3"></a>

###### Prior therapy, home parenteral nutrition, performance status, and hospice consideration at entry

> “All individuals had received and were refractory to at least 3 standard-of-care therapies, including diazoxide, short- and long-acting somatostatin analogs, everolimus, and/or corticosteroids.”
> “Two individuals initiated ersodetug prior to hospitalization, including one receiving continuous carbohydrate supplementation via home TPN.”
> “Four of the 8 individuals had a baseline ECOG score of 3, 1 had an ECOG of 2, and 3 had an ECOG of 1.”
> “Two individuals were under hospice consideration at baseline due to refractory hypoglycemia, progressive disease, and lack of remaining tumor-directed treatment options.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.2-4"></a>

###### Demographics, tumor, and organ function by patient in the peer-reviewed case series

| Characteristic | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Gender; age (years) | “M; 55” | “F; 50” | “F; 50” | “F; 43” | “M; 74” | “M; 62” | “F; 74” | “M; 24” |
| Country | “U.S.” | “U.S.” | “U.S.” | “U.S.” | “U.S.” | “U.S.” | “U.S.” | “The Netherlands” |
| Race/ethnicity | “White, Hispanic” | “White, Non-Hispanic” | “White, Non-Hispanic” | “White, Non-Hispanic” | “White, Non-Hispanic” | “White, Non-Hispanic” | “White, Non-Hispanic” | “White, Non-Hispanic” |
| Diagnosis | “Metastatic Insulinoma” | “Metastatic Insulinoma” | “Neuroendocrine Carcinoma of the Cervix” | “Metastatic Insulinoma” | “Metastatic Insulinoma” | “Metastatic Insulinoma” | “Metastatic Insulinoma” | “Metastatic Insulinoma” |
| Diagnosis year | “2021” | “2015” | “2022” | “2021” | “2023” | “2019” | “2022” | “2022” |
| Tumor primary site | “Pancreas” | “Pancreas” | “Cervix (neuroendocrine carcinoma)” | “Pancreas” | “Pancreas (primary pancreatic NET with liver metastases)” | “Pancreas (well-differentiated pancreatic NET)” | “Pancreas (well-differentiated NET in pancreatic body)” | “Pancreas (primary insulinoma diagnosed 2022; right-sided hemihepatectomy in 2024 at time of insulinoma)” |
| Ki-67 (% and biopsy site) | “8% (liver metastasis biopsy)” | “17.6% (liver resection specimen); primary pancreatic tumor Ki-67 9%” | “75% (liver metastasis biopsy)” | “5% (pancreatic primary tumor)” | “35% (liver metastasis; secondary tumor)” | “Unknown (fine-needle aspiration showing well-differentiated pancreatic NET)” | “42% (liver core needle biopsy; WHO grade 3 well-differentiated NET)” | “16% (pancreatic primary); 17.8% (liver metastasis)” |
| Metastatic sites and burden | “Multiple abdominal and multilobar hepatic lesions, abdominal pain” | “Liver, gastrohepatic lymph nodes, osseous metastases” | “Extensive metastatic burden (Multilobar liver and pelvic metastases)” | “Extesive metastatic burden (Liver, lymph nodes, bone)” | “Extensive liver tumor burden” | “Liver, periportal lymph nodes, para-aortic lymph nodes, low overall disease burden” | “Extensive bilobar hepatic metastatic burden; left hilar metastasis” | “Extensive liver tumor burden, involving an estimated 33% of the remaining left hemi-liver” |
| Hepatic function at initiation | “Mild ↑ transaminases, low albumin” | “Marked ↑ transaminases, low albumin” | “Mild ↑ in alk phos, low albumin” | “Marked ↑ alk phos, low albumin” | “Mild ↑ alk phos, low albumin” | “Modest ↑ transaminases” | “Moderate ↑ alk phos” | “Mild ↑ transaminases, and alk phos” |
| ALT, AST (U/L) | “81, 38” | “148, 144” | “22. 17” | “20, 53” | “36, 26” | “87, 75” | “44, 20” | “40, 44” |
| Alkaline phosphatase (U/L) | “105” | “620” | “173” | “677” | “108” | “104” | “255” | “161” |
| Albumin (g/dL) | “3.4” | “3.1” | “3.4” | “3.1” | “3.1” | “3.9” | “3.8” | “3.8” |
| PT (sec) | “NA” | “16.9” | “18.4” | “12” | “11.3” | “11.5” | “13.9” | “NA” |
| INR (ratio) | “1.1” | “NA” | “NA” | “NA” | “1.0” | “1.0” | “1.2” | “1.1” |
| Renal function at initiation | “Normal” | “Normal” | “Impaired” | “Mildly impaired” | “Normal” | “Normal” | “Normal” | “Mildly impaired” |
| Creatinine (mg/dL) | “1.2” | “0.8” | “2.13” | “1.26” | “1.1” | “0.9” | “0.63” | “1.3” |
| eGFR (mL/min/1.73 m2) | “NA” | “90” | “49” | “54” | “>60” | “>60” | “93” | “73” |

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.2-5"></a>

###### Hospitalization, performance status, and prior antihypoglycemic therapy by patient in the peer-reviewed case series

| Characteristic | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Length of hospitalization before ersodetug (days) | “28” | “NA (ambulatory)” | “15” | “49” | “34” | “NA (ambulatory)” | “4” | “16” |
| Hospice planning before ersodetug | “Y” | “N” | “Y” | “N” | “N” | “N” | “N” | “N” |
| Baseline ECOG | “3” | “2” | “3” | “3” | “3” | “1” | “1” | “1” |
| Number of therapies for hypoglycemia (medications and IV glucose) before ersodetug | “4” | “6” | “4” | “5” | “4” | “2” | “3” | “2” |
| Diazoxide | “+” | “+” | “+” | “+” | “Previously Tried” | “Previously Tried” | “Previously Tried” | “+” |
| Short-acting somatostatin analog (octreotide or pasireotide) | “Previously Tried” | “+” | “+” | “Previously Tried” | “+” | “NA” | “Previously Tried” | “Previously Tried” |
| Long-acting somatostatin analog (lanreotide) | “−” | “+” | “NA” | “+” | “NA” | “+” | “Previously Tried” | “NA” |
| mTOR inhibitor (everolimus) | “+” | “+” | “NA” | “+” | “+” | “+” | “+” | “NA” |
| Corticosteroid (dexamethasone, prednisone) | “+” | “+” | “+” | “+” | “+” | “NA” | “+” | “NA” |
| GIR at ersodetug initiation (mg/kg/min) | “6.0” | “7.0” | “5.1” | “6.2” | “4.9” | “NA” | “5.6” | “3.1” |

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.2-6"></a>

###### Baseline characteristics by patient in the company table of 9 patients

| Characteristic | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | Patient 9 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Gender (M/F) / age (years) | “M / 55” | “F / 50” | “F / 50” | “F / 43” | “M / 74” | “M / 62” | “M / 74” | “M / 53” | “M / 24” |
| Diagnosis | “Metastatic Insulinoma” | “Metastatic Insulinoma” | “Neuroendocrine Carcinoma of the Cervix” | “Metastatic Insulinoma” | “Metastatic Insulinoma” | “Metastatic Insulinoma” | “Metastatic Insulinoma” | “Metastatic Proinsulinoma” | “Metastatic Insulinoma” |
| Number of antihypoglycemic therapies at enrollment | “4” | “3” | “3” | “4” | “4” | “3” | “5” | “2” | “4” |
| GIR at ersodetug initiation (mg/kg/min) | “6.0” | “7.0 (home TPN)” | “5.1” | “6.2” | “4.9” | “n/a (ambulatory)” | “5.6” | “Unknown amount” | “3.1” |
| Length of hospitalization before ersodetug (days) | “28” | “n/a (ambulatory)” | “15” | “49” | “34” | “n/a (ambulatory)” | “4” | “Unknown duration” | “16” |
| Baseline ECOG | “3” | “2” | “3” | “3” | “3” | “1” | “1” | “3” | “1” |

Source: [Rezolute EAP patient profiles (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926001556/tm262357d1_ex99-2.htm)

<a id="topic-3.1.2.8.2-7"></a>

###### Patients and tumor types in the NANETS 2024 poster

| Patient | Gender | Age | Tumor type |
| --- | --- | --- | --- |
| Patient 1 | “M” | “55” | “Metastatic Insulinoma” |
| Patient 2 | “F” | “50” | “Metastatic Insulinoma” |
| Patient 3 | “F” | “50” | “Metastatic Insulin-Secreting Tumor (Cervical Primary)” |
| Patient 4 | “F” | “43” | “Metastatic Insulinoma” |
| Patient 5 | “M” | “74” | “Metastatic Insulinoma” |

Source: [Strosberg et al. (2024)](https://rezolutebio.com/wp-content/uploads/2025/10/NANETS-2024-Poster_Final.pdf)

<a id="topic-3.1.2.8.2-8"></a>

###### Parenteral dextrose and hospital setting at entry in the NANETS 2024 poster

> “At program entry, all patients required continuous parenteral dextrose, including 4 in a prolonged hospital setting.”

Source: [Strosberg et al. (2024)](https://rezolutebio.com/wp-content/uploads/2025/10/NANETS-2024-Poster_Final.pdf)

<a id="topic-3.1.2.8.2-9"></a>

###### Single published case: presentation, tumor, and biochemistry

> “A 55-year-old man presented with a 5-month history of abdominal pain and weight loss.”
> “A liver biopsy revealed a pancreatic neuroendocrine tumor”
> “with a pathogenic MEN1 mutation.”
> “Hormonal analysis, performed when the venous glucose level was 41 mg per deciliter (2.3 mmol per liter), revealed inappropriately high levels of insulin, at 45 μIU per milliliter (312 pmol per liter; reference value, <19.6 μIU per milliliter [141 pmol per liter]); C-peptide, at 6.5 ng per milliliter (reference range, 0.80 to 3.85); and proinsulin, at 453 pmol per liter (reference value, <18).”

Source: [Osataphan et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10506502/)

<a id="topic-3.1.2.8.2-10"></a>

###### Single published case: refractory hypoglycemia on maximal therapy before ersodetug

> “Intravenous 50% dextrose solution was infused through a central line, at a rate of up to 60 ml (30 g) per hour, which reflects very high glucose use.”
> “Despite enteral nutrition support and treatment with high-dose diazoxide, everolimus, dexamethasone, pasireotide, and glucagon, the patient remained hypoglycemic, with up to 58% of all sensor glucose values in each 24-hour period being less than 70 mg per deciliter [3.9 mmol per liter] and up to 19% being less than 54 mg per deciliter (3.0 mmol per liter)”

Source: [Osataphan et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10506502/)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### Summary of glycemic outcomes in the peer-reviewed case series

> “Most patients experienced improved glycemic control, including discontinuation of parenteral glucose in 6 of the 7 applicable patients (median, 4.5 days) and a 35.6% relative reduction from baseline in time in hypoglycemia (<70 mg/dL) by continuous glucose monitoring (mean 12.4-8.0%; pseudo-median paired change of -3.8 percentage points [90% CI, −8.2 to −1.1]; P = .02).”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.3-2"></a>

###### Discontinuation of parenteral glucose: 6 of 7 participants

> “Six of 7 individuals on parenteral glucose support at baseline discontinued it within the 90-day post-therapy window (median time, 4.5 days), which allowed for subsequent reductions in other standard-of-care antihypoglycemic therapies.”
> “One individual on home TPN initiated ersodetug contemporaneously with ablation of primary hepatic metastases, ultimately achieving a 50% reduction in intravenous carbohydrate support after dose escalation of ersodetug to 9 mg/kg biweekly.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.3-3"></a>

###### Number of antihypoglycemic therapies before and after initiation

> “The total number of therapies decreased from a mean of 3.8 to 1.6 during the 90 days after ersodetug initiation (median change, −2.5; 90% CI, −3.5 to −1.0; P = .02)”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.3-4"></a>

###### Time to discontinuation of each antihypoglycemic therapy by patient (days unless stated)

| Therapy | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| IV glucose | “74 (slow taper)” | “139 (50% reduction)” | “4” | “5” | “2” | “NA” | “3” | “42” |
| Diazoxide | “111” | “10” | “4” | “21” | “NA” | “NA” | “NA” | “Ongoing” |
| Short-acting somatostatin analog (octreotide or pasireotide) | “NA” | “18” | “4” | “NA” | “8” | “NA” | “NA” | “NA” |
| Long-acting somatostatin analog (lanreotide) | “NA” | “Ongoing” | “NA” | “30” | “NA” | “Ongoing” | “NA” | “NA” |
| mTOR inhibitor (everolimus) | “∼6 months” | “18” | “NA” | “Ongoing” | “8” | “Ongoing” | “Ongoing” | “NA” |
| Corticosteroid (dexamethasone, prednisone) | “∼7 months” | “∼4 months” | “4 days” | “Ongoing” | “NA” | “NA” | “Ongoing” | “NA” |

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.3-5"></a>

###### Hospital discharge, tumor-directed therapy, performance status, and survival by patient

| Outcome | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Time to discharge from hospital (days) | “84” | “NA” | “7” | “15” | “9” | “NA” | “9” | “1” |
| Hospitalization days in month after initiation | “30” | “0” | “7” | “8” | “8” | “0” | “16” | “1” |
| Chemotherapy within 8 weeks (yes/no; therapy) | “Y; LuTate” | “Y; FOLFOX” | “Y; Pembrolizumab” | “Y; CAPTEM” | “Y; LuTate” | “NA” | “Y; FOLFOX” | “Y; CAPTEM” |
| Surgery within 8 weeks (yes/no; procedure) | “N” | “Y; Whipple Surgery and Left Hepatectomy” | “Y; Total hysterectomy and bilateral oophorectomy” | “Y; Partial Pancreatectomy” | “N” | “N” | “N” | “Y; Hemi-hepatectomy” |
| Other medical procedure within 8 weeks (yes/no; type) | “N” | “Y; HACE” | “N” | “Y; HAE” | “Y; HAE” | “Y; HAE” | “Y; HAE” | “NA” |
| ECOG at 3 months | “0” | “2” | “0” | “0” | “0” | “0” | “1” | “0” |
| Overall survival | “14 months” | “5 months” | “5 months” | “14 months” | “17 months (living)” | “14 months (living)” | “6 months” | “10 months” |
| Cause of death | “Tumor progression” | “Tumor progression” | “Tumor progression” | “Tumor progression” | “NA” | “NA” | “MDS Progression/Sepsis” | “Tumor Progression” |

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.3-6"></a>

###### Time below 70 mg/dL, time below 54 mg/dL, and hyperglycemia by continuous glucose monitoring

> “Seven of 8 individuals achieved a reduction in percent time in hypoglycemia, with a mean decrease from 12.4% at baseline to 8.0% after receiving ersodetug (35.6% relative reduction), equating to a median absolute change of −3.8% (90% CI, −8.2 to −1.1; P = .02)”
> “Percent time in Level 2 hypoglycemia (<54 mg/dL) also trended numerically lower, with a mean decrease from 2.6% at baseline to 1.9% after receiving ersodetug (median absolute change of −0.5%; 90% CI, −2.9 to 1.3; P = .38).”
> “Reductions in overnight percent time in overall and Level 2 hypoglycemia were also observed, but statistical evidence was limited.”
> “No hyperglycemia-related adverse events or need for insulin were reported.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.3-7"></a>

###### Continuous glucose monitoring parameters over 24 hours, by day, and by night

| Period and parameter | Baseline, 90 days before initiation: mean (min, max) | Evaluable period, 90 days after initiation: mean (min, max) | Relative change from baseline (%) | Median change from baseline (90% CI) | P value |
| --- | --- | --- | --- | --- | --- |
| 24 hours: mean sensor glucose (mg/dL) | “117.0 (86.9, 157.6)” | “138.0 (94.3, 189.5)” | “18.0” | “21.6 (6.5, 36.1)” | “0.02” |
| 24 hours: time above 180 (%) | “10.1 (0.6, 29.3)” | “22.7 (0.2, 56.1)” | “124.4” | “13.5 (2.9, 24.3)” | “0.02” |
| 24 hours: time between 70 and 180 (%) | “77.4 (61.0, 95.0)” | “69.2 (43.9, 87.3)” | “−10.6” | “−8.2 (−20.2, 4.8)” | “0.08” |
| 24 hours: time below 70 (%) | “12.4 (1.7, 25.9)” | “8.0 (0.0, 22.4)” | “−35.6” | “−3.8 (−8.2, −1.1)” | “0.02” |
| 24 hours: time below 54 (%) | “2.6 (0.0, 5.2)” | “1.9 (0.0, 6.8)” | “−29.2” | “−0.5 (−2.9, 1.3)” | “0.38” |
| Day (06:00 to 00:00): mean sensor glucose (mg/dL) | “117.2 (86.9, 155.7)” | “139.5 (99.0, 191.2)” | “19.0” | “21.8 (9.5, 36.9)” | “0.008” |
| Day: time above 180 (%) | “10.4 (0.7, 31.7)” | “23.2 (0.3, 57.7)” | “123.0” | “12.9 (3.8, 23.7)” | “0.02” |
| Day: time between 70 and 180 (%) | “76.8 (58.2, 95.0)” | “69.4 (42.3, 92.6)” | “−9.6” | “−6.2 (−19.7, 7.4)” | “0.25” |
| Day: time below 70 (%) | “12.8 (0.8, 27.5)” | “7.3 (0.0, 22.3)” | “−42.6” | “−4.6 (−11.6, −0.7)” | “0.02” |
| Day: time below 54 (%) | “2.7 (0.0, 4.5)” | “2.0 (0.0, 7.2)” | “−26.8” | “−0.7 (−2.8, 1.4)” | “0.46” |
| Night (00:00 to 06:00): mean sensor glucose (mg/dL) | “116.4 (87.0, 163.3)” | “134.2 (80.3, 196.6)” | “15.2” | “15.6 (−3.1, 43.2)” | “0.11” |
| Night: time above 180 (%) | “9.3 (0.0, 26.4)” | “21.6 (0.0, 57.4)” | “132.1” | “9.3 (0.6, 26.7)” | “0.02” |
| Night: time between 70 and 180 (%) | “79.3 (69.4, 95.0)” | “68.3 (42.0, 90.8)” | “−13.9” | “−7.5 (−23.9, −1.0)” | “0.02” |
| Night: time below 70 (%) | “11.3 (0.8, 26.0)” | “10.0 (0.0, 28.8)” | “−11.8” | “−1.1 (−4.5, 2.6)” | “0.25” |
| Night: time below 54 (%) | “2.5 (0.0, 7.6)” | “1.6 (0.0, 5.4)” | “−37.1” | “−1.1 (−4.8, 2.4)” | “0.55” |

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.3-8"></a>

###### Continuous glucose monitoring sensitivity analysis

> “In a sensitivity analysis that incorporated all available CGM data beyond the initial 90-day windows for patients with evaluable recordings, clinical patterns remained consistent with the primary analysis”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.3-9"></a>

###### Hospital discharge and tumor-directed therapy after initiation

> “The median time to hospital discharge after initiation of ersodetug was 9 days (range, 1-84); all patients hospitalized at baseline (n = 6) were discharged to home for treatment, including 2 who were previously considering hospice-level care.”
> “Within 8 weeks of ersodetug initiation, nearly all individuals (n = 7) were able to proceed with tumor-directed therapies, including chemotherapy (n = 7), surgery (n = 4), and other medical procedures such as hepatic arterial embolization (n = 5).”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.3-10"></a>

###### Performance status at 3 months

> “ECOG performance status was evaluated 3 months after initial ersodetug administration; 6 individuals had a score of 0, 4 of whom improved from a baseline score of 3.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.3-11"></a>

###### Response by starting dose

> “Glycemic stabilization was achieved across dosing regimens, with a more pronounced response observed in individuals initiated at 9 mg/kg weekly.”
> “More protracted responses to ersodetug and longer times to hospital discharge in initially treated individuals were associated with lower starting doses and less frequent administration of ersodetug (6 mg/kg and/or biweekly administration).”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.3-12"></a>

###### ENDO 2026 poster: 7 of 8 patients on parenteral glucose with at least 50% reduction

> “Seven of the 8 patients receiving parenteral glucose at baseline achieved at least a 50% reduction (‘responder’; highlighted in table above)”
> “associated with marked to complete reduction in parenteral glucose dependence and enhanced functional status”

Source: [Patti et al. (2026)](https://rezolutebio.com/wp-content/uploads/2026/06/PSTR006_RZLT_ENDO-poster_Tumor-H_3x4_ssREL.pdf)

<a id="topic-3.1.2.8.3-13"></a>

###### Glucose infusion rate, hospitalization, and performance status outcomes by patient in the company table of 9 patients

| Outcome | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | Patient 9 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Percent reduction in GIR by 8 weeks | “>50%, then 100% by 9 weeks” | “<50%” | “100%” | “100%” | “100%” | “n/a” | “100%” | “Unknown amount” | “100%” |
| Time to IV glucose discontinuation (days) | “74” | “139 (achieved 50% reduction)” | “4” | “5” | “2” | “n/a” | “3” | “n/a” | “42” |
| Hospitalized days in the 30 days after initiation | “30” | “0” | “7” | “8” | “8” | “0” | “16” | “30” | “1” |
| ECOG at month 3 | “0” | “2” | “0” | “0” | “0” | “0” | “1” | “5” | “0” |

Source: [Rezolute EAP patient profiles (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926001556/tm262357d1_ex99-2.htm)

<a id="topic-3.1.2.8.3-14"></a>

###### Company summary: 75% of patients on IV dextrose or parenteral nutrition discontinued it

> “In summary, 75% of the patients receiving IV dextrose/total parenteral nutrition (TPN) in the EAP achieved a complete discontinuation of IV dextrose/TPN.”

Source: [Rezolute sunRIZE and EAP insights release (2026)](https://ir.rezolutebio.com/news/detail/369/rezolute-provides-insights-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-and-shares-findings-from-its-expanded-access-program-in-tumor-hyperinsulinism)

> “Complete discontinuation of IV dextrose/total parenteral nutrition (TPN) in 75% of patients”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-3.1.2.8.3-15"></a>

###### NANETS 2024 poster: 4 of 5 patients discontinued parenteral dextrose

> “Four  patients achieved complete discontinuation, and one achieved a 50% reduction in intravenous carbohydrate support after dose increase to 9mg/kg.”
> “Three patients achieved complete resolution of hypoglycemia within two weeks of starting treatment.”
> “More protracted responses occurred in patients who initially received ersodetug at a lower dose or frequency.”

Source: [Strosberg et al. (2024)](https://rezolutebio.com/wp-content/uploads/2025/10/NANETS-2024-Poster_Final.pdf)

<a id="topic-3.1.2.8.3-16"></a>

###### Single published case: hypoglycemia, dextrose infusion, and discharge after ersodetug

> “After the second RZ358 infusion (at a dose of 6 mg per kilogram of body weight), the hypoglycemia attenuated, with less than 1% of all sensor glucose values in each 24-hour period being less than 54 mg per deciliter, a result that permitted a reduction in the rate of dextrose infusion.”
> “After four additional infusions of RZ358 (each at a dose of 9 mg per kilogram), metabolic stability allowed discontinuation of other therapies, despite persistent excessive insulin secretion, elevated lactate dehydrogenase level”
> “Initiation of the anti–insulin receptor monoclonal antibody RZ358 (day 0) was successful in reducing the frequency of hypoglycemia, and the patient was able to safely receive a second dose of LU (day 67), which allowed for discharge home on day 83 after initiation of RZ358 therapy.”
> “The patient has remained free of severe hypoglycemia after 9 months of RZ358 therapy, currently administered at monthly intervals, with no evidence of adverse effects.”

Source: [Osataphan et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10506502/)

<a id="topic-3.1.2.8.3-17"></a>

###### Second patient: insulin-secreting cervical cancer

> “The patient began receiving treatment with RZ358 in September 2023, which resulted in resolution of her hypoglycemia and enabled her to be discharged from the hospital to resume cancer-directed therapy while continuing to receive RZ358 to control hypoglycemia.”

Source: [Rezolute tumor HI evidence release (2023)](https://ir.rezolutebio.com/news/detail/318/rezolute-announces-further-evidence-of-rz358s-efficacy-in-tumor-mediated-hyperinsulinism)

Additional sources: [Schubert et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37888935/); [Osataphan et al. (2023b)](https://pubmed.ncbi.nlm.nih.gov/37888936/)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.2.8.4-1"></a>

###### No quality of life instrument: functional benefit reported as clinician-rated performance status

> “With improvements in glycemic control, all individuals experienced associated functional benefits, including hospital discharge in previously prolonged inpatient cases, and marked improvements in ECOG performance status.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.4-2"></a>

###### Resumption of daily activities, as stated by the company without a measurement instrument

> “Ability to resume regular daily activities (e.g., driving)”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

> “Ability to resume normal activities (e.g., walking, driving, traveling)”

Source: [Rezolute investor event presentation (2025)](https://www.sec.gov/Archives/edgar/data/1509261/000110465925109559/tm2530840d1_ex99-1.htm)

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### Serious adverse events and drug-related events in the peer-reviewed case series

> “No drug-related serious adverse events were observed.”
> “Ersodetug was generally safe and well tolerated among all individuals and across all dose levels and regimens.”
> “There were no drug-related deaths, adverse drug reactions, discontinuations due to adverse events, treatment-emergent clinically significant laboratory abnormalities indicative of organ toxicity, or other dose-limiting toxicities, as determined by treating physicians and reviewed by the sponsor's safety committee.”
> “As depicted in Table 4, 3 of 8 individuals experienced serious adverse events, all attributed to underlying tumor progression or tumor-directed therapies.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.5-2"></a>

###### Treatment-emergent serious adverse events, pooled cohort of 8

| Measure | Pooled cohort (n = 8), number (%) |
| --- | --- |
| Individuals with serious TEAEs, n (%) | “3 (37.5%)” |
| Total SAEs | “4” |
| Individuals with PI-judged study drug-related SAEs, n (%) | “0 (0%)” |
| Grade 1 (mild) | “1 (12.5%)” |
| Grade 2 (moderate) | “0 (0%)” |
| Grade 3 (severe) | “2 (25%)” |
| Grade 4 (life-threatening) | “1 (12.5%)” |
| Grade 5 (death) | “0 (0%)” |

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.5-3"></a>

###### Disease progression not counted as an adverse event, and hyperglycemia

> “Disease progression was not reported as a treatment-emergent adverse event, as per EAP treatment guidelines.”
> “A corresponding increase in time above 180 mg/dL was observed, but without associated clinical impact.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.5-4"></a>

###### ENDO 2026 poster: no drug-related serious adverse events in 9 patients

> “All patients tolerated ersodetug with no drug-related serious adverse events”

Source: [Patti et al. (2026)](https://rezolutebio.com/wp-content/uploads/2026/06/PSTR006_RZLT_ENDO-poster_Tumor-H_3x4_ssREL.pdf)

<a id="topic-3.1.2.8.5-5"></a>

###### NANETS 2024 poster: tolerability in 5 patients

> “Ersodetug was generally safe and well-tolerated, and patients were able to stop or substantially reduce parenteral dextrose, enabling hospital discharge after initiating therapy.”

Source: [Strosberg et al. (2024)](https://rezolutebio.com/wp-content/uploads/2025/10/NANETS-2024-Poster_Final.pdf)

<a id="topic-3.1.2.8.5-6"></a>

###### Company statement on side effects

> “Substantial hypoglycemia improvement with no significant side effects”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

- Design: the peer-reviewed report is a retrospective case series of 8 individuals treated under single-patient compassionate use, with no control group. The authors used nominal P-values without formal or prespecified hypothesis testing, could not construct 95% intervals, and developed the statistical analysis plan after the primary analyses.
- Confounding: within 8 weeks of starting ersodetug, 7 individuals received chemotherapy, 4 had surgery, and 5 had other procedures such as hepatic arterial embolization, which can also reduce hypoglycemia. Doses and schedules changed during the program, and the first 2 individuals were treated under an earlier framework at a lower weekly dose.
- Inconsistent counts and data: the number of patients differs by source (5 in the NANETS 2024 poster, 8 in the publication, 9 in the company table and ENDO 2026 poster). The company table and the publication differ in a patient's sex (“F; 74” and “M / 74”), and the publication gives hospitalization at entry as “median, 28 days; range, 4-66 days” in its text while its table lists a longest stay of 49 days. A company release describes the 9 patients as having malignant insulinoma and non-islet cell tumors, while the case-level tables list insulin-secreting tumors.
- Overlap: the first patient's glucose data were previously published as a single case report, so that case is not independent evidence.
- Safety ascertainment: disease progression was not reported as an adverse event under the program guidelines.

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/); [Strosberg et al. (2024)](https://rezolutebio.com/wp-content/uploads/2025/10/NANETS-2024-Poster_Final.pdf); [Patti et al. (2026)](https://rezolutebio.com/wp-content/uploads/2026/06/PSTR006_RZLT_ENDO-poster_Tumor-H_3x4_ssREL.pdf); [Rezolute EAP patient profiles (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926001556/tm262357d1_ex99-2.htm); [Rezolute ENDO presentations release (2026)](https://ir.rezolutebio.com/news/detail/380/rezolute-highlights-results-presented-from-natural-history-outcomes-studies-and-its-ersodetug-clinical-program-in-hyperinsulinism-at-annual-meeting-of-the-endocrine-society)

<a id="heading-3.1.3"></a>

#### 3.1.3 sunRIZE

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Objective in the ClinicalTrials.gov record

> “The Phase 3 pivotal study is designed to evaluate the efficacy and safety of RZ358 for the treatment of congenital hyperinsulinism (HI) as add-on to standard-of-care (SOC) therapy compared to SOC alone over 24 weeks and to evaluate the longer-term safety and efficacy of RZ358 during a subsequent open-label extension (OLE) period.”

Source: [ClinicalTrials.gov NCT06208215](https://clinicaltrials.gov/study/NCT06208215)

<a id="topic-3.1.3.1-2"></a>

###### Objective and population stated by the company

> “The Phase 3 sunRIZE study (RZ358-301) is a multi-center, randomized, double-blind, placebo-controlled, parallel arm study designed to evaluate the efficacy and safety of ersodetug in patients with congenital hyperinsulinism (HI), ages 3 months to 45 years old, who are experiencing continued hypoglycemia on currently available standard of care (SOC).”

Source: [Rezolute sunRIZE topline release (2025)](https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism)

<a id="topic-3.1.3.1-3"></a>

###### Relevance of the congenital HI trial to tumor HI stated by the company

> “Based on historical precedent, supportive data from the sunRIZE study (i.e., safety and drug activity), the recent liberalization of the tumor HI study and differentiation between study endpoints, and the experience that we have reported”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Study dates and status in the ClinicalTrials.gov record

> “Study Start (Actual) 2024-01-11”
> “Primary Completion (Actual) 2025-11-14”
> “Study Completion (Estimated) 2027-11-14”
> “First Posted 2024-01-17”
> “Last Update Posted 2026-01-08”
> “Active, not recruiting”

Source: [ClinicalTrials.gov NCT06208215](https://clinicaltrials.gov/study/NCT06208215)

<a id="topic-3.1.3.2-2"></a>

###### Number of locations in the ClinicalTrials.gov record

> “This study has 18 locations”

Source: [ClinicalTrials.gov NCT06208215](https://clinicaltrials.gov/study/NCT06208215)

<a id="topic-3.1.3.2-3"></a>

###### Study locations by country in the ClinicalTrials.gov record

| Country | Locations listed in the record |
| --- | --- |
| United States | “Philadelphia, Pennsylvania, United States, 19104”; “Fort Worth, Texas, United States, 76104” |
| Bulgaria | “Varna, Bulgaria, 9010” |
| Denmark | “Odense, Denmark, 5000” |
| France | “Bron, France, 69677”; “Paris, France, 75015” |
| Georgia | “Tbilisi, Georgia, 0159” |
| Germany | “Berlin, Germany, 13353”; “Düsseldorf, Germany, 40225” |
| Greece | “Athens, Greece, 115 27” |
| Oman | “Seeb, Oman, 123” |
| Qatar | “Al Rayyan, Qatar” |
| Spain | “Barcelona, Spain, 08035”; “Seville, Spain, 41013” |
| Turkey (Türkiye) | “Ankara, Turkey (Türkiye), 06800” |
| United Kingdom | “London, United Kingdom, WC1N 3JH”; “Manchester, United Kingdom, M13 9WL” |
| Vietnam | “Hà Nội, Vietnam, 100000” |

Source: [ClinicalTrials.gov NCT06208215](https://clinicaltrials.gov/study/NCT06208215)

<a id="topic-3.1.3.2-4"></a>

###### Countries and U.S. enrollment stated by the company

> “The study enrolled 63 participants in more than a dozen countries around the world, inclusive of U.S. patients.”

Source: [Rezolute sunRIZE topline release (2025)](https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism)

<a id="topic-3.1.3.2-5"></a>

###### Completion of enrollment

> “which completed enrollment in May 2025”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

<a id="topic-3.1.3.2-6"></a>

###### Announcement of topline results

> “REDWOOD CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT)”
> “today announced topline results from its Phase 3 sunRIZE study evaluating ersodetug in patients with congenital hyperinsulinism (HI).”

Source: [Rezolute sunRIZE topline release (2025)](https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Design in the ClinicalTrials.gov record

> “A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Evaluate the Efficacy and Safety of RZ358 in Patients With Congenital Hyperinsulinism”
> “This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled (SOC alone), parallel-arm, efficacy, and safety study of RZ358 in participants with congenital HI who have not achieved adequate hypoglycemia control with reasonable attempts at using usual SOC medical therapy.”
> “Allocation : Randomized”
> “Masking Description: Double blind”

Source: [ClinicalTrials.gov NCT06208215](https://clinicaltrials.gov/study/NCT06208215)

<a id="topic-3.1.3.3-2"></a>

###### Randomization scheme and open-label infant arm in the ClinicalTrials.gov record

> “The study will randomize approximately 48 participants (≥1 year to ≤45 years of age) in a 1:1 ratio into 2 dosing arms (5 or 10 mg/kg with) and further randomize participants within each dosing level in a 2:1 ratio to receive RZ358 as add-on to SOC or placebo as add-on to SOC.”
> “An additional open-label (OL) arm will be conducted in parallel for participants who are ≥3 months to <1 year old (n=8)”
> “Upon completion of the pivotal treatment period (24-weeks), participants may roll-over to the OLE period at the discretion of the investigator and Sponsor.”

Source: [ClinicalTrials.gov NCT06208215](https://clinicaltrials.gov/study/NCT06208215)

<a id="topic-3.1.3.3-3"></a>

###### Treatment periods and open-label extension in the congress presentation

> “Double-Blind Comparator Control Groups”
> “Initial 8 patients ages 3 months – 1 yr enrolled in open-label arm (making total planned enrollment 56)”
> “Open Label Extension”
> “Long-term safety, efficacy durability, efficacy in monotherapy”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Inclusion criteria in the ClinicalTrials.gov record

> “At screening, aged ≥ 3 months and ≤ 45 years old.”
> “An established clinical diagnosis of congenital HI (hyperinsulinism), with or without identification of a known monogenic variant by genetic testing.”
> “Participant has failed to achieve adequate glycemic control with appropriate and reasonable trials of locally accepted and available Standard of Care (SOC) medical therapies (e.g., diazoxide and somatostatin analogs (SSAs)) per the judgment of the investigator.”
> “Experiencing ≥ 3 hypoglycemia events per week by screening Self-Monitoring Blood Glucose (SMBG) and average daily percent time with hypoglycemia of ≥ 8% of the monitored screening Continuous Glucose Monitor (CGM) time.”

Source: [ClinicalTrials.gov NCT06208215](https://clinicaltrials.gov/study/NCT06208215)

<a id="topic-3.1.3.4-2"></a>

###### Exclusion criteria in the ClinicalTrials.gov record

> “Alanine aminotransaminase (ALT), aspartate aminotransaminase (AST), total bilirubin (TB), alkaline phosphatase (ALP), and gamma-glutamyl transferase (GGT) ≥ 1.5 × the upper limit of normal for the age-specific reference range, regardless of assessed significance.”
> “A known clinical diagnosis of diabetes or pre-diabetes, or a history of insulin dependency within 3 months of screening.”
> “Average daily percent time with hyperglycemia ≥ 5% of the monitored screening continuous glucose monitoring (CGM) time.”
> “Known allergy or sensitivity to RZ358 or any component of the drug.”

Source: [ClinicalTrials.gov NCT06208215](https://clinicaltrials.gov/study/NCT06208215)

<a id="topic-3.1.3.4-3"></a>

###### Body mass index exclusion in the ClinicalTrials.gov record

> “Body mass index (BMI) ≥ 35 kg/m2 for participants aged 18 years and above”
> “(no BMI exclusion for participants ≤ 12 years of age).”

Source: [ClinicalTrials.gov NCT06208215](https://clinicaltrials.gov/study/NCT06208215)

<a id="topic-3.1.3.4-4"></a>

###### Key inclusion criteria in the congress presentation

> “Ages 3 months – 45 years”
> “Biochemically established diagnosis of cHI”
> “Persistent hypoglycemia despite SoC”
> “SMBG: >3 hypo (<70 mg/dL) per week”
> “CGM: >8% avg daily time <70 mg/dL”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Treatment arms in the ClinicalTrials.gov record

> “Participants ≥1 year old who receive SOC therapy and 5 mg/kg of RZ358 or placebo”
> “Participants ≥1 year old who receive SOC therapy and 10 mg/kg of RZ358 or placebo”
> “Infant participants from ≥3 months to <1 year old who receive SOC therapy + RZ358 starting at 5 mg/kg and increasing to 10 mg/kg of RZ358, as needed, per the protocol schedule”

Source: [ClinicalTrials.gov NCT06208215](https://clinicaltrials.gov/study/NCT06208215)

<a id="topic-3.1.3.5-2"></a>

###### Dose, schedule, and background therapy stated by the company

> “Eligible participants are randomized to one of three treatment arms to receive either ersodetug (5 or 10 mg/kg) or matched placebo-control as add on to existing SOC. Study drug is administered every other week during an initial loading phase, and then every 4 weeks during the 6-month controlled pivotal treatment period.”
> “At the study dose regimens of 5 and 10 mg/kg administered every other week for 3 doses, followed by every 4 weeks over the remainder of the 24-week treatment duration”

Source: [Rezolute sunRIZE topline release (2025)](https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism)

<a id="topic-3.1.3.5-3"></a>

###### Route and infusion duration of ersodetug

> “30-min IV infusion given every 2-4 weeks”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

<a id="topic-3.1.3.5-4"></a>

###### Dosing in the open-label extension

> “Following the pivotal treatment phase of the study, participants may roll-over into an optional open-label extension phase to continue to receive ersodetug.”

Source: [Rezolute sunRIZE topline release (2025)](https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism)

> “PI discretion: 5 or 10mg/kg dosing Q2-4 weeks, adjustment in SoC”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Weekly Hypoglycemia Events by Self-monitored Blood Glucose as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Primary outcome in the ClinicalTrials.gov record

> “Change in average weekly hypoglycemia events from baseline by point-of-care Self-Monitoring Blood Glucose (SMBG)”

Source: [ClinicalTrials.gov NCT06208215](https://clinicaltrials.gov/study/NCT06208215)

<a id="topic-3.1.3.6.1-2"></a>

###### Key secondary outcome in the ClinicalTrials.gov record

> “Change in average daily percent time in hypoglycemia from baseline by Continuous Glucose Monitor (CGM)”

Source: [ClinicalTrials.gov NCT06208215](https://clinicaltrials.gov/study/NCT06208215)

<a id="topic-3.1.3.6.1-3"></a>

###### Primary and key secondary endpoints stated by the company

> “The primary and key secondary efficacy endpoints in the study are the change from baseline in the average number of hypoglycemia events per week and the average percent time in hypoglycemia, respectively, over six months of treatment.”

Source: [Rezolute sunRIZE topline release (2025)](https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism)

<a id="topic-3.1.3.6.1-4"></a>

###### Other glycemic outcomes in the ClinicalTrials.gov record

> “Proportion of participants experiencing no potentially serious hypoglycemia events by SMBG.”
> “Change in average weekly incidence of potentially serious hypoglycemia events by Self-Monitoring Blood Glucose (SMBG).”
> “Change in average daily percent time with potentially serious hypoglycemia by Continuous Glucose Monitor (CGM).”
> “Change in average 8-hour overnight percent time with hypoglycemia by CGM.”

Source: [ClinicalTrials.gov NCT06208215](https://clinicaltrials.gov/study/NCT06208215)

<a id="topic-3.1.3.6.1-5"></a>

###### Safety outcomes in the ClinicalTrials.gov record

> “Hepatic ultrasound: evaluated for significant structural changes (e.g. peliosis Hepatitis)”
> “Immunogenicity assessments: Blood samples for anti-drug antibody to RZ358 will be evaluated based on the titer, and potential neutralization effects.”
> “24 weeks, plus up to two years of Open-Label Extension (OLE) period”

Source: [ClinicalTrials.gov NCT06208215](https://clinicaltrials.gov/study/NCT06208215)

<a id="topic-3.1.3.6.1-6"></a>

###### Limitations of self-monitored blood glucose metrics acknowledged by the FDA

> “FDA acknowledged the challenges posed by the potential impact of varied behavioral factors on clinical trials in this heterogeneous patient population, including the associated limitations of self-monitored blood glucose (SMBG) based metrics in measuring hypoglycemia in congenital HI.”
> “While acknowledging these challenges, the agency reiterated the expectation for adequate and well-controlled studies and outcomes as the standard for evaluating substantial evidence of efficacy criteria as the basis for approving new therapies.”

Source: [Rezolute congenital HI FDA meeting release (2026)](https://ir.rezolutebio.com/news/detail/373/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting)

<a id="topic-3.1.3.6.1-7"></a>

###### Unblinded self-monitored glucose as a source of bias stated by the company

> “The Company believes that the unblinded nature of self-monitored glucose necessary for patient standard of care, together with perceptions of treatment assignment, may have led to divergent behaviors between treatment groups during the study, which may have impacted the measurement of hypoglycemia by SMBG.”

Source: [Rezolute congenital HI FDA meeting release (2026)](https://ir.rezolutebio.com/news/detail/373/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting)

> “with a particular impact on the primary endpoint of hypoglycemia events by SMBG due to measurement bias associated with infrequent measurement”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

<a id="topic-3.1.3.6.1-8"></a>

###### Glucose monitoring as both safety tool and endpoint in an ambulatory trial

> “The magnitude of the placebo response observed for hypoglycemia events reveals a significant challenge in studying glucose in an ambulatory setting, where factors such as intensive monitoring where caregivers receive alerts regarding hypoglycemic events and frequent clinical interactions can independently influence outcomes.”
> “The Company believes that the extent of reduction from baseline in hypoglycemia events and time in hypoglycemia relative to placebo (see Figure 2) may have been impacted by the prolonged treatment duration of six months and the fact that glucose monitoring is necessary for safe patient management while also serving as the key endpoint in the study.”

Source: [Rezolute sunRIZE and EAP insights release (2026)](https://ir.rezolutebio.com/news/detail/369/rezolute-provides-insights-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-and-shares-findings-from-its-expanded-access-program-in-tumor-hyperinsulinism)

<a id="topic-3.1.3.6.1-9"></a>

###### Key secondary endpoint: percent time in hypoglycemia by continuous glucose monitoring

> “Primary endpoint (SMBG weekly hypoglycemia events) not met”
> “Likely influenced by caregiver behavioral adaptations in hypoglycemia avoidance”
> “CGM metrics showed consistent and clinically meaningful reductions in hypoglycemia”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

<a id="topic-3.1.3.6.1-10"></a>

###### Contrast with the inpatient glucose infusion rate endpoint of the tumor HI trial

> “Notably, the GIR assessment in the EAP is the primary endpoint in upLIFT, which measures the number of participants (out of ~16) who achieve at least a 50% reduction in GIR, an objective endpoint in a highly controlled hospital setting.”

Source: [Rezolute sunRIZE and EAP insights release (2026)](https://ir.rezolutebio.com/news/detail/369/rezolute-provides-insights-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-and-shares-findings-from-its-expanded-access-program-in-tumor-hyperinsulinism)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Planned power for the primary endpoint

> “Powered to show at least a 35% difference between each treatment arm and placebo”

Source: [Rezolute investor event presentation (2025)](https://www.sec.gov/Archives/edgar/data/1509261/000110465925109559/tm2530840d1_ex99-1.htm)

<a id="topic-3.1.3.7.1-2"></a>

###### Planned enrollment in the ClinicalTrials.gov record

> “Enrollment (Estimated) 56”
> “The study will randomize approximately 48 participants (≥1 year to ≤45 years of age)”

Source: [ClinicalTrials.gov NCT06208215](https://clinicaltrials.gov/study/NCT06208215)

<a id="topic-3.1.3.7.1-3"></a>

###### Planned and actual enrollment stated by the company

> “Overall enrollment of 63 participants exceeded target of 56”

Source: [Rezolute investor event presentation (2025)](https://www.sec.gov/Archives/edgar/data/1509261/000110465925109559/tm2530840d1_ex99-1.htm)

<a id="topic-3.1.3.7.1-4"></a>

###### Participants by treatment group

> “RZ358 5 mg/kg (N=18)”
> “RZ358 10 mg/kg (N=20)”
> “Placebo (N=17)”
> “Overall [+OLA] (N=63)”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

<a id="topic-3.1.3.7.1-5"></a>

###### Participants in the per protocol set

> “in the Per Protocol Set (PPS)* (n=41)”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

###### Analysis window and effect measure

> “at the defined Week 24 evaluable window”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

> “Outcomes (LS-Mean [95% CI] Percent Change from Baseline; FAS Population)”
> “Not statistically significant at SAP-specified Week 24/EOT analysis window (-32%; p=0.30 at 10 mg/kg)”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

<a id="topic-3.1.3.7.2-2"></a>

###### Pre-specified, post-hoc, and sensitivity analyses submitted to the FDA

> “In June 2026, the Company submitted source and analysis datasets, and summary results from a substantial number of pre-specified, post-hoc, and sensitivity analyses.”

Source: [Rezolute pre-BLA recommendation release (2026)](https://ir.rezolutebio.com/news/detail/385/rezolute-announces-fda-recommendation-to-hold-a-pre-bla-meeting-as-a-precursor-to-submitting-a-biologics-license-application-bla-for-congenital-hyperinsulinism)

<a id="topic-3.1.3.7.2-3"></a>

###### Per protocol set

> “Per-Protocol Set (PPS): Defined in blinded fashion prior to database lock and excludes participants with below threshold SMBG/CGM data collection, significant escalation in background SOC, and early discontinuations.”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

<a id="topic-3.1.3.7.2-4"></a>

###### Full analysis set

No evidence found.

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

###### Completion of the controlled period and entry into the open-label extension

> “All 59 participants who completed the study elected to continue to receive ersodetug in the OLE.”

Source: [Rezolute sunRIZE and EAP insights release (2026)](https://ir.rezolutebio.com/news/detail/369/rezolute-provides-insights-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-and-shares-findings-from-its-expanded-access-program-in-tumor-hyperinsulinism)

<a id="topic-3.1.3.8.1-2"></a>

###### Early terminations due to adverse events

> “4 early terminations due to adverse events (2 serious hypersensitivity reactions, 1 infusion reaction, 1 mild hypertrichosis)”

Source: [Rezolute January corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926001556/tm262357d1_ex99-3.htm)

<a id="topic-3.1.3.8.1-3"></a>

###### Retention in the open-label extension, January 2026

> “To date, 57 participants remain in the OLE, with an exposure duration ranging from ~6 weeks for the most recently entered patients, to ~18 months.”

Source: [Rezolute sunRIZE and EAP insights release (2026)](https://ir.rezolutebio.com/news/detail/369/rezolute-provides-insights-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-and-shares-findings-from-its-expanded-access-program-in-tumor-hyperinsulinism)

<a id="topic-3.1.3.8.1-4"></a>

###### Retention in the open-label extension, June 2026

> “All 59 participants rolled-over into the open-label extension after the pivotal treatment period”
> “57 still ongoing”
> “Cumulative duration of OLE participation: ~7-25 months”

Source: [ENDO Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/06/ENDO_2026_ORF10_sunRIZE_Demirbilek_13June.pdf)

<a id="topic-3.1.3.8.1-5"></a>

###### Retention in the open-label extension, September 2026

> “To date, 56 participants remain in the OLE, with an exposure duration ranging from ~9 months for the most recently entered patients, to more than 24 months.”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

> “which had 56 participants continuing on the open-label extension as of September 30, 2026.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

<a id="topic-3.1.3.8.1-6"></a>

###### Treatment duration in the open-label extension, November 2026

> “The OLE phase of the study is ongoing, with a continued high retention rate, equating to an ersodetug treatment duration in sunRIZE from approximately one year to well over two years.”

Source: [Rezolute prospectus supplement (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926126478/tm2627558-6_424b5.htm)

<a id="topic-3.1.3.8.1-7"></a>

###### Planned conclusion of the open-label extension

> “The OLE phase of sunRIZE remains ongoing at the present time, but we are evaluating the appropriate timing to conclude the sunRIZE study OLE and move patients into its EAP, depending in part on outcomes from pending FDA interactions”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

###### Demographics, background therapy, and baseline glycemia of the enrolled population

| Parameter | Ersodetug 5 mg/kg | Ersodetug 10 mg/kg | Placebo | Overall, including open-label arm |
| --- | --- | --- | --- | --- |
| Number of participants | “(N=18)” | “(N=20)” | “(N=17)” | “(N=63)” |
| Age in years, mean (range) | “3.4 (1-15 y)” | “3.9 (5 mo to 9 y)” | “4.0 (5 mo to 10 y)” | “3.4 (3 mo to 15 y)” |
| Female, n (%) | “8 (44%)” | “10 (50%)” | “7 (41%)” | “31 (49%)” |
| Genetics, KATP / other or unknown, n (%) | “13 (72%) / 5 (28%)” | “11 (55%) / 9 (45%)” | “15 (88%) / 2 (12%)” | “47 (75%) / 16 (25%)” |
| Current standard of care therapy | “17 (94%)” | “18 (90%)” | “17 (100%)” | “60 (95%)” |
| Diazoxide, n (%) | “9 (50%)” | “11 (55%)” | “5 (29%)” | “26 (41%)” |
| Somatostatin analog, n (%) | “10 (56%)” | “11 (55%)” | “14 (82%)” | “46 (73%)” |
| Scheduled enteral tube feeding, n (%) | “7 (39%)” | “7 (35%)” | “7 (41%)” | “24 (38%)” |
| Two or more therapies, n (%) | “8 (44%)” | “9 (45%)” | “8 (47%)” | “29 (46%)” |
| Pancreatectomy, n (%) | “2 (11%)” | “3 (15%)” | “2 (12%)” | “8 (13%)” |
| Pre-study use of CGM, n (%) | “8 (44%)” | “11 (55%)” | “9 (53%)” | “32 (51%)” |
| Congenital HI-related hospitalizations in previous year, n (%) | “6 (33%)” | “12 (66%)” | “10 (59%)” | “32 (51%)” |
| Hypoglycemia events per week by SMBG, mean (range) | “12.7 (5-42.0)” | “13.4 (4-37)” | “11.7 (3-22)” | “12.6 (3-42)” |
| Percent time in hypoglycemia by CGM, mean (range) | “23.1 (5-73)” | “20.0 (6-71)” | “13.0 (7-38)” | “19.1 (5-73)” |
| HbA1c, mean % (range) | “4.96 (3.9-5.9)” | “5.01 (3.9-6.0)” | “5.32 (4.2-6.2)” | Not reported |
| Average glucose by SMBG, mean mg/dL | “81” | “82” | “86” | Not reported |
| Hypoglycemia Fear Survey worry score, mean | “27.1” | “28.2” | “34.6” | Not reported |

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

<a id="topic-3.1.3.8.2-2"></a>

###### Preliminary baseline summary reported in November 2025

> “Average age of 3.4 years (range: 3m – 15y)”
> “Average of 15 hypoglycemia events/week by SMBG”
> “Average daily percent time in hypoglycemia on CGM of 19%”
> “40% on DZ”
> “67% on SSAs”
> “13% had previous pancreatectomy”

Source: [Rezolute investor event presentation (2025)](https://www.sec.gov/Archives/edgar/data/1509261/000110465925109559/tm2530840d1_ex99-1.htm)

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

###### Primary endpoint: weekly hypoglycemia events by self-monitored blood glucose not met

> “The study did not meet its primary endpoint, which assessed change in the average weekly hypoglycemia events by self monitored blood glucose. There was an approximate 45% reduction in hypoglycemia events observed at the top ersodetug dose (10 mg/kg), which was not statistically significant compared to the placebo group, which experienced a 40% improvement.”

Source: [Rezolute sunRIZE topline release (2025)](https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism)

> “Study Effect on Unblinded SMBG Occurred Early in Dosing:”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

<a id="topic-3.1.3.8.3-2"></a>

###### Key secondary endpoint: percent time in hypoglycemia by continuous glucose monitoring not met

> “Furthermore, the study did not meet its key secondary endpoint, which assessed change in average daily percent time in hypoglycemia by continuous glucose monitoring (CGM). At the 10 mg/kg dose of ersodetug, an approximate 25% reduction in time in hypoglycemia was observed, which was not statistically significant compared to the placebo, which increased by approximately 5%.”

Source: [Rezolute sunRIZE topline release (2025)](https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism)

> “Not statistically significant at SAP-specified Week 24/EOT analysis window (-32%; p=0.30 at 10 mg/kg)”
> “p=0.44”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

<a id="topic-3.1.3.8.3-3"></a>

###### Percent time in hypoglycemia by continuous glucose monitoring at earlier time points, full analysis set

> “Reductions of >50% compared to placebo with nominal statistical significance at the noted timepoints”
> “# Significant reduction vs PBO (p<0.05; both doses) at Week 16;”
> “p≤0.1 at Weeks 8 (both doses) and 20 (5 mg/kg)”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

<a id="topic-3.1.3.8.3-4"></a>

###### Percent time in hypoglycemia by continuous glucose monitoring, per protocol set

> “Reductions of ~60-80% compared to placebo with nominal statistical significance at the noted timepoints”
> “Not statistically significant at SAP-specified Week 24/EOT analysis window (-55%; p=0.18 at 10 mg/kg)”
> “p=0.28”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

<a id="topic-3.1.3.8.3-5"></a>

###### Pre-specified and post-hoc continuous glucose monitoring endpoints

> “Average weekly hypoglycemia events by CGM : clinically relevant and nominally statistically significant reductions of ~50-65% (FAS) and ~50-80% (PPS), compared to placebo across multiple timepoints”
> “Average daily AUC 70 to 180 mg/dL (Exposure to Normoglycemia) by CGM : clinically relevant and nominally statistically significant increases of ~25-50% (FAS and PPS), compared to placebo across multiple timepoints”
> “Average blood glucose (mg/dL) by CGM : clinically relevant and nominally statistically significant increases of ~10-15% (~10-15 mg/dL) in both the FAS and PPS, compared to placebo across multiple timepoints”

Source: [Rezolute sunRIZE PES presentation release (2026)](https://ir.rezolutebio.com/news/detail/375/rezolute-announces-oral-presentation-of-results-from-its-phase-3-sunrize-study-of-ersodetug-in-patients-with-congenital-hyperinsulinism-at-the-pediatric-endocrine-society-annual-meeting)

> “including but not limited to 50% or greater reductions in both average daily percent time in hypoglycemia and average weekly hypoglycemia events.”

Source: [Rezolute FDA review update release (2026)](https://ir.rezolutebio.com/news/detail/383/rezolute-provides-update-on-fda-review-of-its-phase-3-sunrize-study-results-in-congenital-hyperinsulinism)

<a id="topic-3.1.3.8.3-6"></a>

###### Drug concentrations and insulin biomarker response

> “At the study dose regimens of 5 and 10 mg/kg administered every other week for 3 doses, followed by every 4 weeks over the remainder of the 24-week treatment duration, ersodetug target drug concentrations were achieved, across all age groups studied.”

Source: [Rezolute sunRIZE topline release (2025)](https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism)

> “Specifically, there was evidence of pharmacologic activity as target therapeutic drug concentrations were achieved in both treatment groups (5 mg/kg and 10 mg/kg) with highly sensitive biomarker responses (increases in circulating insulin) in the active treatment groups that are indicative of reduced insulin activity at its receptor.”

Source: [Rezolute sunRIZE and EAP insights release (2026)](https://ir.rezolutebio.com/news/detail/369/rezolute-provides-insights-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-and-shares-findings-from-its-expanded-access-program-in-tumor-hyperinsulinism)

<a id="topic-3.1.3.8.3-7"></a>

###### Preliminary open-label extension observations

> “Glycemic improvement from baseline across multiple endpoints (e.g. average glucose by SMBG, hypoglycemia events by SMBG, HbA1c)”
> “Notably also in the rolled-over placebo participants compared to the controlled period of the study”
> “Concurrent overall reduction in background SoC (e.g, diazoxide, somatostatin analogs, and/or regular tube feeds)”
> “Including discontinuation of other therapies and use of ersodetug in monotherapy in many instances”
> “Data preliminary and in flux in ongoing OLE”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

<a id="topic-3.1.3.8.3-8"></a>

###### FDA Type B meeting on the efficacy results, March 2026

> “As a next step for the program, FDA encouraged the Company to submit study reports and analysis datasets for the agency’s independent evaluation. Following that review, the Company believes that a determination may be made whether there is sufficient evidence to support the submission of a marketing application for sunRIZE or if additional information is required.”

Source: [Rezolute congenital HI FDA meeting release (2026)](https://ir.rezolutebio.com/news/detail/373/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting)

<a id="topic-3.1.3.8.3-9"></a>

###### FDA review of the submitted datasets and pre-BLA recommendation, October 2026

> “The Agency has reviewed the data and, despite the trial’s failure to meet the prespecified primary and key secondary endpoints, as a next step, encouraged the Company to request a Type B pre-BLA meeting as a precursor to submitting a BLA for congenital HI. The Agency explicitly did not opine on the approvability of ersodetug for congenital HI and noted that any such determination would only be made as a part of an in-depth evaluation of the supporting data during a formal BLA review, as is customary during a BLA process.”

Source: [Rezolute pre-BLA recommendation release (2026)](https://ir.rezolutebio.com/news/detail/385/rezolute-announces-fda-recommendation-to-hold-a-pre-bla-meeting-as-a-precursor-to-submitting-a-biologics-license-application-bla-for-congenital-hyperinsulinism)

<a id="topic-3.1.3.8.3-10"></a>

###### Timing of the pre-BLA meeting and possibility of a further randomized study

> “The Company expects to request a pre-BLA meeting with the Agency to take place during the first half of calendar year 2027.”
> “The FDA may require us to provide additional information or conduct additional clinical studies, including another study similar to sunRIZE, which could delay the submission or approval of a BLA, increase our costs and require changes to our operating plans.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

<a id="topic-3.1.3.8.3-11"></a>

###### Possible effect of the sunRIZE results on the FDA assessment of the tumor HI trial

> “we have previously asked the FDA whether it will consider the results of the sunRIZE trial when considering additional regulatory steps related to ersodetug, including whether the results of the sunRIZE trial will impact the FDA’s assessment of any results that we may receive from the upLIFT trial.”
> “Although the FDA has not historically grouped trial results in this way, in the event the FDA takes this approach in connection with ersodetug this could significantly impact our business and future plans.”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.3.8.4-1"></a>

###### Patient-reported quality of life outcomes under evaluation

> “The Company is currently exploring how to characterize the overall study dynamic including evaluating patient-reported quality of life outcomes.”

Source: [Rezolute sunRIZE and EAP insights release (2026)](https://ir.rezolutebio.com/news/detail/369/rezolute-provides-insights-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-and-shares-findings-from-its-expanded-access-program-in-tumor-hyperinsulinism)

<a id="topic-3.1.3.8.4-2"></a>

###### Patient and family experience in the open-label extension

> “Favorable patient/family reported experiences overall”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Overall adverse events and adverse drug reactions

> “Adverse events occurred in ~90% of participants at a comparable rate across treatment groups”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

> “Safety observations from the study were generally favorable and, in the opinion of the Company, support safe use of ersodetug in pediatric and adult patients.”

Source: [Rezolute sunRIZE topline release (2025)](https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism)

<a id="topic-3.1.3.8.5-2"></a>

###### Hypersensitivity reactions

> “Two of the study participants experienced serious hypersensitivity reactions which led to early discontinuation of study drug. The incidence of serious allergic reactions across the program is relatively low compared to biologic or monoclonal antibody treatments.”

Source: [Rezolute sunRIZE topline release (2025)](https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism)

> “Hypersensitivity reactions led to early discontinuation of study drug in 3 participants”
> “Two participants with serious allergic reactions (including anaphylaxis)”
> “Resolved quickly upon discontinuation of study drug”
> “Overall program incidence of ~2%”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

<a id="topic-3.1.3.8.5-3"></a>

###### Hypertrichosis

> “The most commonly reported study adverse event in ersodetug treated participants compared to placebo was hypertrichosis, which was generally mild and self-limiting.”

Source: [Rezolute sunRIZE topline release (2025)](https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism)

> “Hypertrichosis was the only other commonly reported AE in ersodetug patients (n=14; 36%)”

Source: [Rezolute January corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926001556/tm262357d1_ex99-3.htm)

> “Excess hair growth (hypertrichosis) was commonly reported in ersodetug treated patients (~35%)”
> “Mild and not dose-dependent”
> “Led to discontinuation of study drug in 1 participant”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

<a id="topic-3.1.3.8.5-4"></a>

###### Hyperglycemia and hepatic safety

> “No clinically-relevant hyperglycemia:”
> “Low rates of transient mild to moderate hyperglycemia without associated sequalae”
> “No hyperglycemia AEs”
> “Hepatic safety: No signal by liver enzymes or ultrasound monitoring”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

> “No liver safety signals”

Source: [Rezolute January corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926001556/tm262357d1_ex99-3.htm)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

- Population: sunRIZE enrolled participants with congenital hyperinsulinism aged 3 months to 45 years, a different disease and a younger population than adults with tumor hyperinsulinism, so its efficacy results are indirect evidence for this report. Its main relevance here is the safety data and its effect on the regulatory assessment.
- Outcome: the trial did not meet its primary or key secondary endpoint. The favorable continuous glucose monitoring results at earlier time points and in the per protocol set are nominal, and the company's explanation of the result (self-monitored measures confounded by functional unblinding through real-time glucose monitoring) is its own interpretation.
- Reporting: results are available only from company releases, filings, and congress slides, with no peer-reviewed publication. Sources differ on the number of discontinuations for hypersensitivity (2 serious reactions in the topline release; 3 participants in the congress slides; 4 early terminations in the January 2026 presentation), on the CGM result at 10 mg/kg (“approximate 25% reduction” against “-32%; p=0.30”), and on hypertrichosis (36% and about 35%). One baseline cell reads “12 (66%)” for 12 of 20 participants. The registry still lists an estimated enrollment of 56.
- The open-label extension is ongoing, and its glycemic observations are described by the company as preliminary.

Source: [ClinicalTrials.gov NCT06208215](https://clinicaltrials.gov/study/NCT06208215); [Rezolute sunRIZE topline release (2025)](https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism); [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf); [Rezolute upLIFT interim release (2026)](https://ir.rezolutebio.com/news/detail/378/rezolute-announces-positive-interim-data-for-its-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism); [Rezolute January corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926001556/tm262357d1_ex99-3.htm)

<a id="heading-3.1.4"></a>

#### 3.1.4 RIZE

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Objective in the trial registry

> “The objective of this trial is to evaluate the safety, tolerability and glucose-raising effects of RZ358 in patients with Congenital Hyperinsulinism (HI).”

Source: [ClinicalTrials.gov NCT04538989](https://clinicaltrials.gov/study/NCT04538989)

<a id="topic-3.1.4.1-2"></a>

###### Objectives in the primary publication

> “The objectives of this study were to evaluate the safety, tolerability, PK, PD, and glycemic efficacy of repeat bi-weekly doses of ersodetug over 8 weeks in participants with cHI.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Study dates in the trial registry

| Milestone | Quoted date |
| --- | --- |
| Study start (actual) | “2020-02-24” |
| Primary completion (actual) | “2022-04-05” |
| Study completion (actual) | “2022-08-19” |

Source: [ClinicalTrials.gov NCT04538989](https://clinicaltrials.gov/study/NCT04538989)

<a id="topic-3.1.4.2-2"></a>

###### Number of centers and countries

> “A total of 16 centers across 11 countries participated in the study.”
> “RIZE was conducted across 11 countries and three continents in order to capture the broadest potential study population to reflect the known heterogeneity of cHI.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.2-3"></a>

###### Study sites listed in the trial registry

| Country | Quoted site |
| --- | --- |
| United States | “The Children's Hospital of Philadelphia” |
| United States | “Cook Children's Medical Center” |
| Canada | “Research Institute of the McGill University Health Centre” |
| Denmark | “Odense University Hospital” |
| Germany | “Magdeburg University Clinic Center (Otto-von-Guericke Universität)” |
| Israel | “Edmond & Lilly Safra's Children Hospital” |
| Israel | “Hadassah Har Hazofim MC - Division of Pediatric Endocrinology” |
| Russia | “Endocrinology research center” |
| Spain | “Hospital Universitari Vall d' Hebron” |
| Turkey | “Adana Cukurova University Balcalı Hospital” |
| Turkey | “Hacettepe University” |
| Turkey | “Erzurum City Hospital” |
| United Kingdom | “Great Ormond Street Hospital” |

Source: [ClinicalTrials.gov NCT04538989](https://clinicaltrials.gov/study/NCT04538989)

<a id="topic-3.1.4.2-4"></a>

###### Topline results announcement

> “today announced positive data from its Phase 2b RIZE study of RZ358.”

Source: [Rezolute RIZE topline release (2022)](https://ir.rezolutebio.com/news/detail/296/rezolute-announces-positive-results-from-the-phase-2b-rize-study-of-rz358-in-congenital-hyperinsulinism)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Open-label, repeat-dose study in four sequential ascending-dose cohorts

> “The RIZE trial was a Phase 2, global, multi-center, open-label, repeat-dose study of ersodetug, conducted in four sequential ascending-dose cohorts in 23 participants with cHI ≥2 years-old with inadequately controlled hypoglycemia on standard-of-care (SOC) therapies.”
> “The study duration was approximately 28 weeks including a Screening Period of up to 35 days, Treatment Period of 8 weeks, and Follow-up Period of ∼3 months.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.3-2"></a>

###### Design description in the trial registry

> “This is a Phase 2, multicenter, open label clinical study designed to assess the safety and efficacy of four progressively higher doses of RZ358 in separate groups of patients with hyperinsulinemic hypoglycemia due to Congenital HI, not adequately controlled with or without current standard of care.”

Source: [ClinicalTrials.gov NCT04538989](https://clinicaltrials.gov/study/NCT04538989)

<a id="topic-3.1.4.3-3"></a>

###### Dose escalation oversight

> “The study was approved by country and local regulatory authorities and ethics committees and was supervised by a Dose Escalation Review Committee (DERC) which included three principal investigators.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.3-4"></a>

###### Add-on to standard of care with unchanged diet and activity

> “Participants continued with their respective SOC and maintained their usual diet and activity levels during the entire study from screening through follow-up.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.3-5"></a>

###### Protocol number and registrations

> “This study was sponsored by Rezolute, Inc. (clinical trial number RZ358-606) and registered at ClinicalTrials.gov (ClinicalTrials.gov: NCT04538989) and EudraCT (2016-004186-83).”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.3-6"></a>

###### Company description of the design

> “RIZE is a Phase 2b, multicenter, open label, repeat-dose study, designed to assess the safety and tolerability, pharmacokinetics, and glycemic efficacy of RZ358 administered bi-monthly for 8 weeks in patients with congenital hyperinsulinism whose hypoglycemia was not adequately controlled on standard of care therapies.”

Source: [Rezolute RIZE topline release (2022)](https://ir.rezolutebio.com/news/detail/296/rezolute-announces-positive-results-from-the-phase-2b-rize-study-of-rz358-in-congenital-hyperinsulinism)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Congenital hyperinsulinism with persistent hypoglycemia despite standard of care

> “Participants between the ages of 2–45 years old with biochemically proven cHI, irrespective of genetic etiology, were eligible for the study if they were experiencing persistent hypoglycemia despite being managed with currently available SOC therapy.”
> “Persistent hypoglycemia was defined as having three or more hypoglycemia events (<70 mg/dL; 3.9 mmol/L) per week by self-monitored blood glucose (SMBG) performed by point of care (POC) glucometer as well as glucose values < 70 mg/dL (3.9 mmol/L) for ≥4% of overall monitored time in a minimum 10-day CGM sensing period, including at least three severe hypoglycemia events (<50 mg/dL; 2.8 mmol/L) by CGM during the last 7 days of the sensing period.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.4-2"></a>

###### Exclusion criteria in the primary publication

> “Exclusion criteria included: those with clinically significant comorbidities, recent history of surgery, clinically significant out-of-range laboratory values (as determined per investigator), recent use of systemic corticosteroids, or adolescents and adults with a body mass index (BMI) in the Class 2 (BMI = 35.0–39.9) or greater obesity range.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.4-3"></a>

###### Inclusion and exclusion criteria in the trial registry, including exclusion of malignancy

> “Male or female age 2-45 years old (except age 12-45 in US) with an established clinical diagnosis of congenital hyperinsulinism”
> “Confirmed hypoglycemia as assessed by CGM, SMBG, and clinical evaluation, during Screening”
> “History of malignancy”
> “Use of systemic corticosteroids within 30 days before Screening”
> “Known or suspected allergy to the study drug”

Source: [ClinicalTrials.gov NCT04538989](https://clinicaltrials.gov/study/NCT04538989)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Dose regimens by cohort in the trial registry

| Cohort | Quoted intervention |
| --- | --- |
| Cohort 1 | “IV infusion for 8 weeks (3 mg/kg bi-weekly for 8 weeks)” |
| Cohort 2 | “IV infusion for 8 weeks (6 mg/kg bi-weekly for 8 weeks)” |
| Cohort 3 | “IV infusion for 8 weeks (9 mg/kg bi-weekly for 8 weeks)” |
| Cohort 4 | “IV infusion for 8 weeks (bi-weekly fixed dose-titration from 3 to 9 mg/kg for the first 4 weeks, followed by a fixed 9 mg/kg dose amount thereafter for the remaining 4 weeks)” |

Source: [ClinicalTrials.gov NCT04538989](https://clinicaltrials.gov/study/NCT04538989)

<a id="topic-3.1.4.5-2"></a>

###### Intravenous infusion over at least 30 minutes every other week, added to standard of care

> “Cohort 1 received 3 mg/kg, Cohort 2 received 6 mg/kg, Cohort 3 received 9 mg/kg, and Cohort 4 was a fixed dose titration cohort starting at 3 mg/kg and ending at 9 mg/kg.”
> “Within their respective dose cohorts, each participant received ersodetug by intravenous (IV) infusion over at least 30 min every other week (bi-weekly) for a total of eight weeks, added to their stable SOC management.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.5-3"></a>

###### Inpatient administration and follow-up visits

> “Enrolled participants were admitted to an inpatient unit at the study center the day prior to the first dose and at each subsequent bi-weekly administration of the study drug.”
> “Following each dose, participants were monitored under inpatient observation for at least 24 h.”
> “During the ∼3-month safety follow-up period, participants completed four outpatient visits at Days 14 (End of Treatment [EOT]), 28, 42, and 105 (final End of Study [EOS] visit) following the final dose of study drug.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.5-4"></a>

###### Rescue therapy

> “Rescue therapy guidelines based on hypoglycemia and hyperglycemia thresholds were provided to standardize the use of rescue therapy across the study, and to optimize the safety of study participants.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using Percent Time in Glucose Target Range 70-180 mg/dL by Continuous Glucose Monitoring as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### Registered primary outcome measures

> “Median of Average Daily Percent Time Within a Glucose Target Range of 70-180 mg/dL (3.9-10 mmol/L) by CGM at Baseline (BL) and End of Treatment (EOT)”
> “Median Percent Change of Average Daily Percent Time Within a Glucose Target Range of 70-180 mg/dL (3.9-10 mmol/L) by CGM From Baseline (BL)”
> “Repeat Dose Pharmacokinetics of RZ358”

Source: [ClinicalTrials.gov NCT04538989](https://clinicaltrials.gov/study/NCT04538989)

<a id="topic-3.1.4.6.1-2"></a>

###### Primary and key secondary glycemic endpoints in the primary publication

> “The key, clinically-relevant glycemic endpoints that were assessed included: change from baseline in the average daily percent-time within a glucose target range of 70–180 mg/dL (3.9–10 mmol/L) by CGM (primary endpoint), and the key secondary endpoints of change from baseline in the average weekly incidence of hypoglycemia events (<70 mg/dL [<3.9 mmol/L] and <50 mg/dL [2.8 mmol/L]) by SMBG, and change from baseline in the average daily percent-time with hypoglycemia (<70 mg/dL[<3.9 mmol/L] and <50 mg/dL [2.8 mmol/L] by CGM.”
> “Secondary and additional CGM-based glycemic endpoints such as measures of overnight hypoglycemia were also evaluated.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.6.1-3"></a>

###### Authors' assessment of time in range as an endpoint in congenital hyperinsulinism

> “Clinical target ranges for CGM have been developed specifically for the diabetes mellitus population, and treatment recommendations in this hyperglycemia-focused setting allow for a greater extent of time above range (>180 mg/dL) than was seen in nearly all ersodetug-treated cHI participants in the RIZE study.”
> “For cHI, a condition of over-insulinization where avoidance of hypoglycemia is the primary management goal, diabetes management guidelines and hyperglycemia avoidance are generally considered far less relevant, and TIR has less utility as a study endpoint for evaluating the efficacy and safety of investigational therapies in cHI.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.6.1-4"></a>

###### Hypoglycemia events and time in hypoglycemia as the clinically relevant outcomes

> “Key hypoglycemia outcomes with clinical relevance to the cHI patient population, namely change in weekly hypoglycemia event rate by SMBG and daily percentage of time in hypoglycemia by CGM, are presented in Table 4.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.6.1-5"></a>

###### Registered secondary outcome measures, including a fasting challenge

> “Median Percent Change of Average Weekly Overall, Moderate, and Severe Hypoglycemia Events by SMBG From Baseline (BL)”
> “Median Percent Change of Average Daily Percent Time With Overall, Moderate, and Severe Hypoglycemia by CGM From Baseline (BL)”
> “The occurrence of hypoglycemia during a 12 Hour fasting challenge.”
> “Median Percent Change of Average 8-hour Overnight Percent Time in Glucose Target Range of 70-180mg/dL by CGM From Baseline (BL)”

Source: [ClinicalTrials.gov NCT04538989](https://clinicaltrials.gov/study/NCT04538989)

<a id="topic-3.1.4.6.1-6"></a>

###### Glucose measurement devices and safety assessments

> “CGM was performed using Dexcom G6 and output into the specified endpoint parameters based on derivations detailed in the study statistical analysis plan.”
> “The interpretation of the safety and tolerability of ersodetug was based on the assessment of adverse events (AEs), vital signs, ECGs, physical examination results, infusion-site observations, hepatic ultrasound results, anti-drug antibody levels, and clinical safety laboratory evaluations.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Planned enrollment per cohort

> “Up to eight participants were to be enrolled into each of the four cohorts, with a requirement for at least three participants to be younger than ten years old in order to progress to the next cohort.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.7.1-2"></a>

###### Sample size not powered for the glycemic endpoints

> “This study and the chosen sample size were not powered to the primary or key secondary pre-specified endpoints.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.7.1-3"></a>

###### Participants analyzed in each population

> “The entire enrolled population (n = 23) was included and analyzed in the intention-to-treat (ITT), safety, and PK populations.”
> “The per protocol (PP) population included 20 and 22 participants for the blood glucose monitor (BGM)- and CGM-based glycemic endpoints, respectively.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.7.1-4"></a>

###### Exclusions from the per-protocol glucometer analyses in the trial registry

> “For efficacy outcomes, the PP Population included 20 participants for BGM-based glycemic endpoints due to endpoint-specific exclusions. One participant in Cohort 1 and one in Cohort 4 were excluded from the PP population BGM-based analyses because they failed to meet pre-specified minimum testing frequency by glucometer. One participant in Cohort 3 was also excluded from the PP population BGM analyses for stopping background SOC therapy after starting RZ358 in the study”

Source: [ClinicalTrials.gov NCT04538989 results](https://clinicaltrials.gov/study/NCT04538989?tab=results)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

###### Safety, pharmacokinetic, and per-protocol populations

> “The PK population (n = 23) comprised all participants who received at least one dose of ersodetug and for whom the obtained concentrations were considered to be sufficient and interpretable.”
> “The per protocol population comprised participants who completed at least 4 weeks of study drug without major protocol deviations and was used for the primary descriptive summaries and comparative analyses of the glycemic efficacy and PD biomarker endpoints. A secondary summary and analyses used the Intent to Treat Population (n = 23).”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.7.2-2"></a>

###### Baseline and end-of-treatment evaluable periods

> “The baseline for glycemic endpoints was a minimum of 10 days and defined as the period of time encompassing all glucose measurements used to qualify the participant’s eligibility and continuing up to the first dose of study medication. The end of treatment (EOT) Evaluable Period for glycemic endpoints was defined as the 2-week period following the final dose of study drug, corresponding to the bi-weekly dosing interval.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.7.2-3"></a>

###### Statistical methods: Wilcoxon signed-rank test of change from baseline

> “Inferential statistical comparisons were performed as appropriate using Wilcoxon sign-rank test (SAS 9.3) to compare and analyze the median change and significance level (p-value) from baseline to the EOT evaluable period.”
> “A stage-dependent and iterative population-PK model (2-compartment with linear clearance) was used to characterize the PK parameters by age group, which were also summarized descriptively.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

###### Screened, enrolled, and completed participants

> “A total of 35 participants were screened for the study, and 23 participants were eligible and enrolled, as per the study design depicted in Figure 1.”
> “Screen failures were most commonly due to failure to meet inclusion criteria, such as the defined threshold of persistent hypoglycemia (n = 8) or the presence of an exclusion criteria (n = 4).”
> “All enrolled participants completed the entire treatment period and all follow-up visits; notably, no enrolled participants discontinued the study for any reason.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.8.1-2"></a>

###### Protocol violations leading to per-protocol exclusion

> “This was due to significant protocol violations that met per-protocol exclusion, including stopping background standard-of-care (SOC) therapy and inadequate self-monitored blood glucose (SMBG) measurement frequency.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.8.1-3"></a>

###### Participant flow in the trial registry

| Milestone | Cohort 1, 3 mg/kg | Cohort 2, 6 mg/kg | Cohort 3, 9 mg/kg | Cohort 4, 3 to 9 mg/kg |
| --- | --- | --- | --- | --- |
| Started | “4” | “8” | “8” | “3” |
| Completed | “4” | “8” | “8” | “3” |
| Not completed | “0” | “0” | “0” | “0” |

Source: [ClinicalTrials.gov NCT04538989 results](https://clinicaltrials.gov/study/NCT04538989?tab=results)

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

###### Demographics and baseline disease characteristics, intention-to-treat population

| Parameter | Cohort 1, 3 mg/kg (n = 4) | Cohort 2, 6 mg/kg (n = 8) | Cohort 3, 9 mg/kg (n = 8) | Cohort 4, 3 to 9 mg/kg (n = 3) | Pooled (n = 23) |
| --- | --- | --- | --- | --- | --- |
| Age in years, mean (range) | “5.8 (2–12)” | “9.3 (2–22)” | “5.8 (2–17)” | “4.0 (2–6)” | “6.7 (2–22)” |
| Male, n | “4” | “5” | “3” | “1” | “13 (57%)” |
| KATP channel mutation, n | “1” | “5” | “4” | “1” | “11 (48%)” |
| Unknown genetic etiology | “3” | “2” | “3” | “1” | “9 (39%)” |
| Congenital HI therapy, n (%) | “4” | “7” | “6” | “3” | “20 (87%)” |
| Diazoxide | “2” | “3” | “1” | “2” | “8 (35%)” |
| Somatostatin analog (long acting/short acting) | “2/0” | “2/2” | “3/3” | “1/0” | “8/5 (52%)” |
| Enteral or tube use | “0” | “2” | “3” | “0” | “5 (22%)” |
| Pancreatectomy | “0” | “0” | “3” | “1” | “4 (17%)” |
| History of seizure, n | “4” | “4” | “5” | “3” | “16 (70%)” |
| Hospitalization within the past year, n | “3” | “3” | “6” | “2” | “14 (61%)” |
| Percent time in range (70–180 mg/dL) by CGM, mean (range) | “82 (74–89)” | “74 (66–89)” | “71 (12–90)” | “68 (57–87)” | “74 (12–90)” |
| Percent time in hypoglycemia (<70 mg/dL) by CGM, mean (range) | “16 (11–22)” | “22 (11–32)” | “24 (6–88)” | “29 (11–42)” | “23 (6–88)” |
| Hypoglycemia events/week (<70 mg/dL) by SMBG, mean (range) | “8 (1–13)” | “16 (4–52)” | “15 (7–29)” | “8 (4–11)” | “13 (1–52)” |

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.8.2-2"></a>

###### Age distribution, background therapy, and history of hospitalization and seizures

> “The study population ranged between 2 and 22 years old and was primarily pediatric, with a mean age of 6.7 years. The majority of participants (19 of 23 [83%]) were <12 years old, including 16 (70%) who were between 2 and 6 years old.”
> “Most participants (20/23 [87%]) were taking one or more stable SOC treatments, such as somatostatin analogs (52%), diazoxide (35%), and/or continuous enteral nutrition (22%), while the remaining participants (3/23, 13%) were not taking commonly used chronic medical therapies due to previous non-responsiveness or intolerance.”
> “At study entry, 14 participants (61%) reported being hospitalized an average of 1.7 times (range 1–4) within the year prior to study enrollment due to cHI-related hypoglycemia or associated complications. Additionally, 16 participants (70%) had a known history of hypoglycemia-related seizures, and nearly half (n = 11 [48%]) experienced either seizures or an altered level of consciousness (ALOC) requiring third-party intervention in the year preceding enrollment.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.8.2-3"></a>

###### Sex, race, and country of enrollment in the trial registry results

| Characteristic | Quoted total (n = 23) |
| --- | --- |
| Female | “13” |
| Male | “10” |
| White | “20” |
| Enrolled in Turkey | “7” |
| Enrolled in Russia | “5” |
| Enrolled in Bulgaria | “3” |

Source: [ClinicalTrials.gov NCT04538989 results](https://clinicaltrials.gov/study/NCT04538989?tab=results)

<a id="topic-3.1.4.8.2-4"></a>

###### Company-reported baseline characteristics

> “The RIZE study enrolled a diverse group of congenital HI patients with an average age of 6.5 years, including 16 patients between the ages of 2 and 6 years old, and with substantial continued hypoglycemia despite being on currently available therapies.”

Source: [Rezolute RIZE PES data release (2022)](https://ir.rezolutebio.com/news/detail/299/rezolute-announces-positive-data-from-its-phase-2b-rize-study-of-rz358-in-patients-with-congenital-hyperinsulinism)

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

###### Primary endpoint: percent time in range 70-180 mg/dL by CGM, per-protocol population

| Measure | Cohort 1, 3 mg/kg (n = 4) | Cohort 2, 6 mg/kg (n = 8) | Cohort 3, 9 mg/kg (n = 7) | Cohort 4, 3 to 9 mg/kg (n = 3) | Pooled (n = 22) |
| --- | --- | --- | --- | --- | --- |
| Median daily percent time in range at baseline | “81.7” | “72.9” | “83.4” | “59.3” | “76.9” |
| Median daily percent time in range at week 8 | “84.8” | “78.5” | “82.9” | “70.8” | “79.1” |
| Median percent change from baseline | “6.19” | “0.31” | “5.52” | “9.07” | “4.59” |

Source: [ClinicalTrials.gov NCT04538989 results](https://clinicaltrials.gov/study/NCT04538989?tab=results)

<a id="topic-3.1.4.8.3-2"></a>

###### Primary endpoint: time in range not significantly changed

> “Due to modest median increases in CGM time in mild hyperglycemia, the significant improvements in hypoglycemia time and events did not translate to a similar magnitude of improvement in CGM time in range (TIR; 70–180 mg/dL). In pooled participants across all dose levels, TIR (70–180 mg/dL) increased by a non-statistically significant median of ∼5%.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.8.3-3"></a>

###### Key secondary endpoints: hypoglycemia events by SMBG and time in hypoglycemia by CGM, per-protocol population

| Metric | Cohort 1, 3 mg/kg (n = 4) | Cohort 2, 6 mg/kg (n = 8) | Cohort 3, 9 mg/kg (n = 7) | Cohort 4, 3 to 9 mg/kg (n = 3) | Pooled, median (range) |
| --- | --- | --- | --- | --- | --- |
| Hypoglycemia events (<70 mg/dL) by BGM, events/week, baseline | “10.1” | “12.5” | “13.0” | “9.3” | “11.5 (4.0–52.0)” |
| Hypoglycemia events (<70 mg/dL) by BGM, events/week, end of treatment | “9.9” | “6.6” | “1.9” | “7.6” | “5.0 (0–23.8)” |
| Hypoglycemia events (<70 mg/dL), % change from baseline (p value) | “−1.6 (NS)” | “−48 (0.016)” | “−84 (0.016)” | “−19.9 (NS)” | “−59 (<0.001)” |
| Severe hypoglycemia events (<50 mg/dL), % change from baseline (p value) | “−40 (NS)” | “−78 (NS)” | “−100 (0.016)” | “−27 (NS)” | “−78 (0.005)” |
| Time in hypoglycemia (<70 mg/dL) by CGM, %, baseline | “16.3” | “20.3” | “13.7” | “34.4” | “16.2 (6–88)” |
| Time in hypoglycemia (<70 mg/dL) by CGM, %, end of treatment | “12.3” | “6.7” | “5.4” | “20.4” | “8.5 (0.3–34)” |
| Time in hypoglycemia (<70 mg/dL), % change from baseline (p value) | “−31 (NS)” | “−65 (0.023)” | “−61 (0.016)” | “−47 (NS)” | “−54 (<0.001)” |
| Time in severe hypoglycemia (<50 mg/dL), % change from baseline (p value) | “−22 (NS)” | “−74 (NS)” | “−85 (NS)” | “−61 (NS)” | “−65 (NS)” |

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.8.3-4"></a>

###### Key secondary endpoints: summary of reductions in hypoglycemia

> “Hypoglycemia (<70 mg/dL) events (self-monitored blood glucose) and time (continuous glucose monitoring) improved from baseline by medians of 59% (p < 0.001) and 54% (p < 0.001), respectively, across pooled dose levels and by 48%–84% (events) and 61%–65% (time) at doses of 6 or 9 mg/kg (p < 0.05) with a nearly universal individual patient response rate.”
> “Cohort 4, who received a fixed titration regimen, experienced blended improvements in total and severe hypoglycemia events of 20% and 27%, respectively. Generally, the observed glycemic changes and p values in cohorts 1 and 4 reflected lower overall doses as well as smaller group sizes.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.8.3-5"></a>

###### Individual responder rates

> “Across all study participants, including the minimally efficacious low dose of 3 mg/kg, there was a consistently high individual patient response rate to ersodetug, as a large majority of participants (88%–100% at the mid- and high-dose levels) achieved corrections in overall hypoglycemia of at least 50% measured by either CGM or SMBG, as shown in Table S2. At the highest dose, all participants achieved at least 50% improvement in severe hypoglycemia (<50 mg/dL), with all but one participant improving by at least 75%.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.8.3-6"></a>

###### Overnight hypoglycemia and time above range, per-protocol population

| Endpoint | Cohort 1, 3 mg/kg | Cohort 2, 6 mg/kg | Cohort 3, 9 mg/kg | Cohort 4, 3 to 9 mg/kg | Pooled |
| --- | --- | --- | --- | --- | --- |
| Overnight (8 h) percent time <70 mg/dL by CGM, % change (p value) | “−15.8 (NS)” | “−54.8 (NS)” | “−55.0 (NS)” | “−61.9 (NS)” | “−52.2 (0.006)” |
| Overnight (8 h) event rate <70 mg/dL by CGM, % change (p value) | “−15.5 (NS)” | “−49.3 (NS)” | “−42.9 (NS)” | “−56.5 (NS)” | “−40.7 (0.04)” |
| Percent time above range (>180 mg/dL) by CGM, net change | “+0.53” | “+6.7” | “+9.4” | “+10.4” | “+6.03” |
| Average overnight glucose (mg/dL) by CGM, net change | “−2.5” | “+21.5” | “+19.3” | “+19.8” | “+17.8” |

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.8.3-7"></a>

###### Overnight hypoglycemia: congress analysis

> “In a dose-dependent manner, across all dose levels, baseline overnight hypoglycemia time (13.6% time [65 min]) improved by a median of 52% (P = 0.001).”
> “Average overnight glucose shifted slightly from baseline median of 99 mg/dL to 113 mg/dL (P <0.001) at EOT.”

Source: [Dastamani et al. (2024)](https://abstracts.eurospe.org/hrp/0098/hrp0098fc14.3)

<a id="topic-3.1.4.8.3-8"></a>

###### Fasting challenge in the trial registry

| Measure | Cohort 1, 3 mg/kg (n = 4) | Cohort 2, 6 mg/kg (n = 8) | Cohort 3, 9 mg/kg (n = 7) | Cohort 4, 3 to 9 mg/kg (n = 3) | Pooled (n = 22) |
| --- | --- | --- | --- | --- | --- |
| Participants able to complete fast at baseline | “3” | “2” | “0” | “0” | “5” |
| Participants able to complete fast at end of treatment | “3” | “1” | “2” | “1” | “7” |

Source: [ClinicalTrials.gov NCT04538989 results](https://clinicaltrials.gov/study/NCT04538989?tab=results)

<a id="topic-3.1.4.8.3-9"></a>

###### Rescue interventions and background therapy

> “During the study’s treatment period, three participants met rescue criteria and received a total of four rescue interventions for hypoglycemia, as determined by the investigator. Of the participants that received rescue interventions, only one participant required i.v. glucose, at a time frame early in the treatment period. No participants required continuous i.v. glucose supplementation at baseline or on treatment.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.8.3-10"></a>

###### Pharmacokinetics and pharmacodynamics

> “As expected of an intravenous (i.v.) medication, the exposures were predictable and dose dependent; plasma concentrations increased approximately proportional to dose across the ersodetug dose range of 3–9 mg/kg (Figure 2). The half-life of ersodetug was approximately 2 weeks.”
> “It was observed that pediatric exposures trended lower than adult exposures, with decreasing pediatric age.”
> “Dose-dependent increases in fasting and/or post-prandial insulin were observed, with average maximal increases of up to ∼10-fold at the 9 mg/kg dose level. Insulin levels declined at the conclusion of the treatment period and returned to baseline levels at approximately 4–6 weeks after stopping the study drug.”
> “Fasting and/or post-prandial BHOB levels, which are characteristically suppressed in cHI, increased dose dependently from baseline by a median of ∼2- to 3-fold across all dose cohorts.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.8.3-11"></a>

###### Company-reported results for the pooled 6 and 9 mg/kg doses

> “Pooled 6 and 9 mg/kg dose levels representative of Phase 3 population and dosing”
> “Improvement in time in hypoglycemia and overall events of ~75% and up to ~90% at top doses”
> “Nearly universal patient response rate (>50% hypoglycemia correction) observed at mid and top doses”

Source: [Rezolute September corporate presentation (2025)](https://www.sec.gov/Archives/edgar/data/1509261/000110465925085892/tm2524786d1_ex99-2.htm)

> “RZ358 led to a better than 50% reduction from baseline in overall (<70 mg/dL) and severe (<50 mg/dL) hypoglycemia events (by BGM) and time in hypoglycemia (by CGM) in the pooled group of patients across all doses (see Table 1). A larger magnitude of improvement of ~75% was seen at the anticipated therapeutic doses of 6 mg/kg and 9 mg/kg.”

Source: [Rezolute RIZE PES data release (2022)](https://ir.rezolutebio.com/news/detail/299/rezolute-announces-positive-data-from-its-phase-2b-rize-study-of-rz358-in-patients-with-congenital-hyperinsulinism)

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

###### Overall safety: no deaths, adverse drug reactions, or discontinuations

> “There were no deaths, adverse drug reactions, discontinuations due to adverse events, treatment-emergent clinically significant organ system findings (e.g., laboratory abnormalities), or dose-limiting toxicities, as reviewed by the dose escalation review committee (DERC).”
> “No treatment-emergent clinically significant abnormalities were found in laboratory evaluations, including hepatic function parameters, or hepatic ultrasound examinations, physical examinations, or electrocardiograms (ECGs).”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.8.5-2"></a>

###### Overview of treatment-emergent adverse events, safety population

| Category | Pre-treatment non-TEAE, total (n = 23) | Cohort 1, 3 mg/kg (n = 4) | Cohort 2, 6 mg/kg (n = 8) | Cohort 3, 9 mg/kg (n = 8) | Cohort 4, titrate (n = 3) | Ersodetug, total (n = 23) |
| --- | --- | --- | --- | --- | --- | --- |
| Participants with adverse events, n (%) | “10 (43)” | “2 (50)” | “7 (88)” | “5 (63)” | “2 (67)” | “16 (70)” |
| Participants with serious adverse events, n (%) | “0 (0)” | “0 (0)” | “2 (25)” | “1 (13)” | “0 (0)” | “3 (13)” |
| Participants with investigator-judged study drug-related adverse events, n (%) | “2 (9)” | “0 (0)” | “2 (25)” | “1 (13)” | “0 (0)” | “3 (13)” |
| Participants with grade 3 (severe) adverse events, n (%) | “1 (4)” | “0 (0)” | “2 (25)” | “0 (0)” | “0 (0)” | “2 (9)” |
| Participants with grade 4 (life threatening) adverse events, n (%) | “0 (0)” | “0 (0)” | “0 (0)” | “1 (13)” | “0 (0)” | “1 (4)” |

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.8.5-3"></a>

###### Most common treatment-emergent adverse events

> “The most commonly reported TEAEs overall (reported by 2 or more of the ersodetug-treated study participants) were upper respiratory tract infection (n = 4, 17%), COVID-19 infection (n = 3, 13%), and anemia (n = 2, 9%). On a time-adjusted basis, there was no meaningful difference in the number of AEs during the study drug treatment period (41 TEAEs in 16 participants) compared to the pre-treatment period (17 non-TEAEs in 10 participants).”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.8.5-4"></a>

###### Serious adverse events

> “A total of three serious AEs occurred in 3 separate participants (hypoglycemia with loss of consciousness, seizure, and white blood cell increase) and were deemed by investigator(s) as related to background disease conditions and unrelated to the study drug and, thus, were not serious adverse reactions.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

| Serious adverse event | Cohort 1, 3 mg/kg | Cohort 2, 6 mg/kg | Cohort 3, 9 mg/kg | Cohort 4, 3 to 9 mg/kg |
| --- | --- | --- | --- | --- |
| “Hypoglycemia with LOC” | “0” | “1” | “0” | “0” |
| “Tonic-Clonic Seizure” | “0” | “0” | “1” | “0” |
| “Eosinophilic Leukocytosis” | “0” | “1” | “0” | “0” |

Source: [ClinicalTrials.gov NCT04538989 results](https://clinicaltrials.gov/study/NCT04538989?tab=results)

<a id="topic-3.1.4.8.5-5"></a>

###### Adverse events judged related to study drug, including infusion site reactions

> “Three participants experienced four non-serious and clinically mild TEAEs judged by investigator(s) to be related to the study treatment, including a 6 mg/kg participant with transient dizziness that followed the first administration of study drug, a 6 mg/kg participant with localized and transient infusion site reactions with the first 2 administrations of the study drug, and a 9 mg/kg participant with hyperactivity, which the investigator attributed to an improvement in hypoglycemia.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.8.5-6"></a>

###### Hyperglycemia

> “A modest, transient, and self-limiting increase in time in hyperglycemia (>180 mg/dL) by CGM from ∼2% at baseline to ∼8% after receiving ersodetug was observed in this study, in which participants were instructed to continue their background therapies. There was no increase in clinically relevant hyperglycemia events, and minimal increases in mild hyperglycemia were not dose dependent. Furthermore, there was no evidence of ketosis, no participant met criteria for and/or required insulin use, and no hyperglycemia-related AEs occurred.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.8.5-7"></a>

###### Immunogenicity

> “One of the 23 enrolled participants had minimally detectable anti-drug antibodies (ADAs), with a low titer of <1:40 and no evidence of immune reaction or neutralizing antibodies against ersodetug.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.8.5-8"></a>

###### Company-reported exposure margin to nonclinical toxicology studies

> “The observed blood levels of RZ358 were well below levels that were safely tested in long term toxicology studies in non-human primates.”

Source: [Rezolute RIZE PES data release (2022)](https://ir.rezolutebio.com/news/detail/299/rezolute-announces-positive-data-from-its-phase-2b-rize-study-of-rz358-in-patients-with-congenital-hyperinsulinism)

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary

- Design: RIZE was an open-label, uncontrolled study of 23 participants with sequential dose cohorts and 8 weeks of treatment, and its sample size was not powered for the primary or key secondary endpoints.
- Population: participants had congenital hyperinsulinism and were 2 years of age or older, so the study provides indirect evidence of efficacy for adults with tumor hyperinsulinism.
- Outcome: the improvements in hypoglycemia did not translate into a similar improvement in time in range, the registry primary endpoint. The registry reports this endpoint as medians in the per protocol population, while the publication reports means in the intention-to-treat population.
- Reporting: the registry results and the publication differ on sex distribution, and the 2022 company releases describe dosing as “bi-monthly” where the publication gives “every other week (bi-weekly)”.

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8); [ClinicalTrials.gov NCT04538989](https://clinicaltrials.gov/study/NCT04538989); [Rezolute RIZE topline release (2022)](https://ir.rezolutebio.com/news/detail/296/rezolute-announces-positive-results-from-the-phase-2b-rize-study-of-rz358-in-congenital-hyperinsulinism); [Rezolute RIZE PES data release (2022)](https://ir.rezolutebio.com/news/detail/299/rezolute-announces-positive-data-from-its-phase-2b-rize-study-of-rz358-in-patients-with-congenital-hyperinsulinism)

<a id="heading-3.1.5"></a>

#### 3.1.5 XOMA 358 First-in-Human Study

<a id="heading-3.1.5.1"></a>

##### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

###### Primary and secondary objectives

> “The primary objective was to assess safety and tolerability, and secondary objectives included PK and PD analyses.”

Source: [Johnson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28605468/)

<a id="topic-3.1.5.1-2"></a>

###### Objectives stated at study start

> “The study also will explore the biologic effects of ascending single IV doses of XOMA 358 on glucose and insulin levels as well as insulin sensitivity.”

Source: [XOMA (2014)](https://investors.xoma.com/news-events/press-releases/detail/258/xoma-launches-xoma-358-clinical-development)

<a id="heading-3.1.5.2"></a>

##### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

###### First participant dosed in October 2014

> “today announced it has initiated dosing in its Phase 1 study exploring the safety and tolerability of single intravenous doses (IV) of XOMA 358, the lead compound from the Company's XMetD program, in healthy volunteers.”

Source: [XOMA (2014)](https://investors.xoma.com/news-events/press-releases/detail/258/xoma-launches-xoma-358-clinical-development)

> “We launched clinical development activities for XOMA 358 in October 2014, with the first patient dosed in our Phase 1 safety and tolerability study.”

Source: [XOMA Form 10-K (2015)](https://www.sec.gov/Archives/edgar/data/791908/000114036115011358/form10k.htm)

<a id="topic-3.1.5.2-2"></a>

###### Completion and presentation in 2015

> “In March 2015, we announced that we successfully completed a Phase 1 clinical study of XOMA 358, a fully human, allosteric monoclonal antibody that attenuates both the binding of insulin to its receptor and downstream insulin signaling.  We have presented the data at the ENDO 2015 meeting and at the American Diabetes Association’s 75th Scientific Sessions.”

Source: [XOMA Form 10-K (2016)](https://www.sec.gov/Archives/edgar/data/791908/000156459016014295/xoma-10k_20151231.htm)

<a id="heading-3.1.5.3"></a>

##### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

###### Double-blind, placebo-controlled, single ascending dose

> “A double-blind, placebo-controlled, single-ascending-dose study was performed with 29 healthy adult males”

Source: [Johnson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28605468/)

<a id="topic-3.1.5.3-2"></a>

###### Dose escalation by cohort

> “Individual cohorts were administered XOMA 358 doses of 0.1, 0.3, 1, and 3 mg/kg or placebo, with dose escalation based on review of safety and pharmacokinetic data from each cohort.”

Source: [XOMA (2015)](https://investors.xoma.com/news-events/press-releases/detail/267/xoma-presents-positive-phase-1-xoma-358-data-at-the-endo)

<a id="heading-3.1.5.4"></a>

##### 3.1.5.4 Eligibility Criteria

Additional sources: [Johnson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28605468/)

<a id="heading-3.1.5.5"></a>

##### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

###### Single intravenous infusion of placebo or 0.1 to 9 mg/kg

> “randomized to intravenous infusion of placebo or X358 at 0.1-, 0.3-, 1-, 3-, 6-, or 9-mg/kg dose levels.”

Source: [Johnson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28605468/)

<a id="topic-3.1.5.5-2"></a>

###### Insulin infusion challenge at 3 mg/kg

> “Subjects who were given a single administration of XOMA 358 at 3 mg/kg were infused with insulin before and 2, 3 and 5 days after dosing.”

Source: [XOMA (2015)](https://investors.xoma.com/news-events/press-releases/detail/267/xoma-presents-positive-phase-1-xoma-358-data-at-the-endo)

<a id="heading-3.1.5.6"></a>

##### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

###### 3.1.5.6.1 Rationale for Using Safety and Tolerability as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

###### Purpose of the first-in-human study: safety, pharmacokinetics, and dose selection

> “In addition to showing the safety and pharmacokinetics of this unique antibody, the study is designed to show relevant biologic activity and inform dose selection for Phase 2 trials.”

Source: [XOMA (2014)](https://investors.xoma.com/news-events/press-releases/detail/258/xoma-launches-xoma-358-clinical-development)

<a id="topic-3.1.5.6.1-2"></a>

###### Pharmacodynamic endpoints: insulin tolerance test and mixed meal test

> “A short insulin tolerance test (ITT) was implemented in the 3- to 9-mg/kg dose cohorts at baseline and postinfusion.”

Source: [Johnson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28605468/)

> “Changes in insulin and glucose were monitored through the use of Mixed meal tests (MMTs) and insulin tolerance tests (ITT).”

Source: [XOMA (2015)](https://investors.xoma.com/news-events/press-releases/detail/267/xoma-presents-positive-phase-1-xoma-358-data-at-the-endo)

<a id="heading-3.1.5.7"></a>

##### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

###### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

###### Interim count at the March 2015 presentation

> “The Phase 1 first-in-human study enrolled 19 healthy volunteer subjects; 14 received XOMA 358 and 5 received placebo.”

Source: [XOMA (2015)](https://investors.xoma.com/news-events/press-releases/detail/267/xoma-presents-positive-phase-1-xoma-358-data-at-the-endo)

> “Results of the study, in which 14 healthy volunteers received XOMA 358 and 5 received placebo, showed XOMA 358 reduced insulin sensitivity and decreased glucose disposal after exogenous insulin injection.”

Source: [XOMA Form 10-Q (2015)](https://www.sec.gov/Archives/edgar/data/791908/000156459015009798/xoma-10q_20150930.htm)

<a id="topic-3.1.5.7.1-2"></a>

###### Healthy volunteer count across phase 1 studies stated in the RIZE publication

> “In previous clinical studies, including two phase 1 single-ascending-dose studies in adult healthy volunteers (n = 22), a combined single-ascending and repeat-dose phase 2 study in adult patients with post-gastric bypass hypoglycemia (n = 16), and two single-ascending-dose phase 2 studies in teen and adult participants with cHI (n = 14), ersodetug was found to be generally safe and well tolerated and resulted in pharmacokinetic (PK) and pharmacodynamic (PD) profiles that support weekly, bi-weekly, and potentially monthly dosing of ersodetug.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="heading-3.1.5.7.2"></a>

###### 3.1.5.7.2 Description of Analysis Sets

Additional sources: [Johnson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28605468/)

<a id="heading-3.1.5.8"></a>

##### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

###### 3.1.5.8.1 Participant Disposition

Additional sources: [Johnson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28605468/)

<a id="heading-3.1.5.8.2"></a>

###### 3.1.5.8.2 Baseline Characteristics

Additional sources: [Johnson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28605468/)

<a id="heading-3.1.5.8.3"></a>

###### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

###### Pharmacokinetics: dose-proportional exposure and half-life

> “X358 exhibited dose-proportional PK with a half-life of 21 days.”

Source: [Johnson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28605468/)

<a id="topic-3.1.5.8.3-2"></a>

###### Pharmacodynamics: insulin as a biomarker of exposure and reduced insulin sensitivity

> “Dose-dependent elevations of circulating insulin levels, likely related to reduced insulin clearance via monoclonal antibody action at receptors, represented a sensitive biomarker of X358 exposure. X358-dependent increases in postprandial glucose levels and fasting homeostatic model assessment of insulin resistance values were observed and persisted for at least 1 week at the higher dose levels. In all the ITT cohorts, the slope for glucose lowering was substantially attenuated after X358 infusion of a similar magnitude, but with increasing duration with rising dose level.”
> “Single X358 infusions were well tolerated and resulted in a dose-dependent reduction in insulin sensitivity.”

Source: [Johnson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28605468/)

<a id="topic-3.1.5.8.3-3"></a>

###### Pharmacodynamics at the interim presentation: postprandial glucose and insulin challenge

> “Dose-related increases in post-prandial (after eating a meal) glucose levels, consistent with down-regulation of insulin signaling, were observed through Day 6 following drug infusion, with the Day 3 glucose AUC nearly 80% greater than placebo at the 1 mg/kg dose level. Fasting HOMA-IR values, a measure of reduced insulin signaling, were likewise elevated in a dose-dependent manner and, at peak time points, were several fold over baseline.”
> “Prior to administration of the drug, as expected, the infusion caused a significant lowering of blood sugar. This lowering of blood sugar was significantly blunted at all subsequent time points tested.”

Source: [XOMA (2015)](https://investors.xoma.com/news-events/press-releases/detail/267/xoma-presents-positive-phase-1-xoma-358-data-at-the-endo)

<a id="heading-3.1.5.8.4"></a>

###### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.5.8.5"></a>

###### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

###### No deaths, serious adverse events, or discontinuations due to adverse events

> “There were no deaths, serious adverse events (AEs), or subject discontinuations due to AEs. There were no clinically meaningful safety findings.”

Source: [Johnson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28605468/)

<a id="topic-3.1.5.8.5-2"></a>

###### Tolerability at the interim presentation

> “XOMA 358 appeared to be well-tolerated; there were no serious adverse events.”

Source: [XOMA (2015)](https://investors.xoma.com/news-events/press-releases/detail/267/xoma-presents-positive-phase-1-xoma-358-data-at-the-endo)

<a id="topic-3.1.5.8.5-3"></a>

###### Clinical testing limited to single-dose studies in adults after phase 1

> “Based on our interactions with the FDA, XOMA 358 clinical testing is currently limited to single-dose studies in adults.  Data has been generated which will be submitted to request expanded testing as part of our clinical development plan.”

Source: [XOMA Form 10-K (2016)](https://www.sec.gov/Archives/edgar/data/791908/000156459016014295/xoma-10k_20151231.htm)

<a id="heading-3.1.5.9"></a>

##### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

###### Summary

- The study enrolled only healthy adult males and gave single doses, so it describes pharmacokinetics, pharmacodynamics, and short-term tolerability without information on repeated dosing or on patients with hyperinsulinism.
- Only the abstract and company releases are openly available; the full text, with eligibility, disposition, baseline characteristics, and adverse event tables, is closed access, and no registry identifier was found. The reported number of healthy volunteers differs across documents (29 in the publication; 22 across two phase 1 studies in a later publication).

Source: [Johnson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28605468/); [XOMA (2015)](https://investors.xoma.com/news-events/press-releases/detail/267/xoma-presents-positive-phase-1-xoma-358-data-at-the-endo); [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
